10-Q

0001076930
false
--12-31
Q3
Unlimited
Unlimited
June 30, 2030
P1Y
http://fasb.org/us-gaap/2025#PropertyPlantAndEquipmentNet
http://fasb.org/us-gaap/2025#PropertyPlantAndEquipmentNet
http://fasb.org/us-gaap/2025#OtherAccruedLiabilitiesCurrent
http://fasb.org/us-gaap/2025#OtherAccruedLiabilitiesCurrent
http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent
http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent
P0Y
http://fasb.org/srt/2025#ChiefExecutiveOfficerMember
366
295
0001076930
us-gaap:CostOfSalesMember
2025-01-01
2025-09-26
0001076930
novt:AutomationEnablingTechnologiesMember
novt:RoboticsAndAutomationMember
2025-06-28
2025-09-26
0001076930
country:CN
2024-06-29
2024-09-27
0001076930
us-gaap:TechnologyBasedIntangibleAssetsMember
2024-12-31
0001076930
novt:RestOfEuropeMember
2024-01-01
2024-09-27
0001076930
novt:TwoThousandTwentyFiveCommonStockRepurchasePlanMember
2025-01-01
2025-09-26
0001076930
novt:KeonnTechnologiesSLMember
2025-04-08
2025-04-08
0001076930
novt:MedicalSolutionsMember
2024-06-29
2024-09-27
0001076930
us-gaap:SellingGeneralAndAdministrativeExpensesMember
2025-01-01
2025-09-26
0001076930
novt:ThomasNSecorMember
2025-06-28
2025-09-26
0001076930
us-gaap:WarrantyObligationsMember
srt:MaximumMember
2025-01-01
2025-09-26
0001076930
novt:EquityIncentivePlanTwentyTenMember
2025-01-01
2025-09-26
0001076930
us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
2025-09-26
0001076930
novt:AutomationEnablingTechnologiesMember
2024-06-29
2024-09-27
0001076930
novt:FiscalYearTwentyTwentyFiveMember
novt:AutomationEnablingTechnologiesMember
2025-06-28
2025-09-26
0001076930
novt:UnallocatedMember
novt:FiscalYearTwentyTwentyFourMember
2025-06-28
2025-09-26
0001076930
novt:AdvancedIndustrialMember
2024-06-29
2024-09-27
0001076930
novt:AutomationEnablingTechnologiesMember
novt:RoboticsAndAutomationMember
2024-06-29
2024-09-27
0001076930
us-gaap:CommonStockMember
2024-01-01
2024-09-27
0001076930
us-gaap:CommonStockMember
2024-06-28
0001076930
us-gaap:AdditionalPaidInCapitalMember
2025-06-28
2025-09-26
0001076930
novt:FiscalYearTwentyTwentyFiveMember
2025-06-27
0001076930
us-gaap:RetainedEarningsMember
2025-01-01
2025-09-26
0001076930
novt:KeonnTechnologiesSLMember
2025-04-08
0001076930
us-gaap:OperatingSegmentsMember
novt:AutomationEnablingTechnologiesMember
2024-06-29
2024-09-27
0001076930
novt:HybridPsusMember
novt:EquityIncentivePlanTwentyTenMember
srt:MinimumMember
2025-01-01
2025-09-26
0001076930
us-gaap:OperatingSegmentsMember
novt:AutomationEnablingTechnologiesMember
2025-06-28
2025-09-26
0001076930
country:DE
2025-01-01
2025-09-26
0001076930
novt:FiscalYearTwentyTwentyFourMember
2025-09-26
0001076930
us-gaap:ForeignCurrencyGainLossMember
us-gaap:ForeignExchangeForwardMember
2025-01-01
2025-09-26
0001076930
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-01-01
2025-09-26
0001076930
us-gaap:SellingGeneralAndAdministrativeExpensesMember
2024-06-29
2024-09-27
0001076930
us-gaap:AdditionalPaidInCapitalMember
2024-09-27
0001076930
novt:FourthAmendedAndRestatedCreditAgreementMember
2025-06-27
2025-06-27
0001076930
us-gaap:RetainedEarningsMember
2024-12-31
0001076930
novt:ProfessionalAndConsultingFeesMember
2024-01-01
2024-09-27
0001076930
us-gaap:CanadaRevenueAgencyMember
country:CA
2025-06-28
2025-09-26
0001076930
country:US
2025-01-01
2025-09-26
0001076930
novt:FiscalYearTwentyTwentyFourMember
novt:AutomationEnablingTechnologiesMember
2024-06-29
2024-09-27
0001076930
novt:SeveranceFacilityRelatedAndOtherChargesMember
novt:FiscalYearTwentyTwentyFourMember
2025-06-28
2025-09-26
0001076930
novt:FacilitySaleMember
2024-12-31
0001076930
2024-09-27
0001076930
us-gaap:AccumulatedTranslationAdjustmentMember
2025-09-26
0001076930
us-gaap:RevolvingCreditFacilityMember
2025-09-26
0001076930
us-gaap:SellingGeneralAndAdministrativeExpensesMember
2025-06-28
2025-09-26
0001076930
us-gaap:CanadaRevenueAgencyMember
country:CA
2024-06-29
2024-09-27
0001076930
us-gaap:AccumulatedTranslationAdjustmentMember
2025-01-01
2025-09-26
0001076930
novt:TermLoanMember
2024-12-31
0001076930
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-06-28
0001076930
srt:MinimumMember
2025-09-26
0001076930
us-gaap:ForeignCurrencyGainLossMember
us-gaap:ForeignExchangeForwardMember
2024-06-29
2024-09-27
0001076930
us-gaap:RetainedEarningsMember
2024-06-29
2024-09-27
0001076930
us-gaap:CommonStockMember
2024-06-29
2024-09-27
0001076930
novt:MedicalSolutionsMember
novt:FiscalYearTwentyTwentyFourMember
2025-01-01
2025-09-26
0001076930
srt:DirectorMember
novt:RestrictedStockUnitsAndDeferredStockUnitsMember
novt:EquityIncentivePlanTwentyTenMember
us-gaap:SellingGeneralAndAdministrativeExpensesMember
2025-01-01
2025-09-26
0001076930
us-gaap:MaterialReconcilingItemsMember
2025-06-28
2025-09-26
0001076930
us-gaap:CorporateNonSegmentMember
2025-01-01
2025-09-26
0001076930
novt:AttainmentBasedPsusMember
novt:EquityIncentivePlanTwentyTenMember
srt:MaximumMember
2025-01-01
2025-09-26
0001076930
novt:AutomationEnablingTechnologiesMember
2024-01-01
2024-09-27
0001076930
us-gaap:FairValueMeasurementsRecurringMember
novt:AccruedExpensesAndOtherCurrentLiabilitiesMember
2025-09-26
0001076930
us-gaap:OperatingSegmentsMember
2025-06-28
2025-09-26
0001076930
novt:MedicalSolutionsMember
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-26
0001076930
novt:KeonnTechnologiesSLMember
us-gaap:TradeNamesMember
2025-04-08
2025-04-08
0001076930
us-gaap:MaterialReconcilingItemsMember
2024-01-01
2024-09-27
0001076930
novt:AttainmentBasedPsusAndHybridPsusMember
2025-01-01
2025-09-26
0001076930
novt:FourthAmendedAndRestatedCreditAgreementMember
novt:EuroTermLoansMember
2025-06-27
2025-06-27
0001076930
novt:MedicalSolutionsMember
novt:PrecisionMedicineMember
2024-06-29
2024-09-27
0001076930
us-gaap:AccumulatedTranslationAdjustmentMember
2024-12-31
0001076930
novt:FourthAmendedAndRestatedCreditAgreementMember
novt:USTermLoanFacilityStartingInSeptemberTwoThousandTwentySixMember
2025-06-27
2025-06-27
0001076930
novt:EquityIncentivePlanTwentyTenMember
us-gaap:EmployeeStockOptionMember
2024-12-31
0001076930
us-gaap:CommonStockMember
2025-09-26
0001076930
us-gaap:ResearchAndDevelopmentExpenseMember
2025-06-28
2025-09-26
0001076930
country:CN
2025-01-01
2025-09-26
0001076930
novt:MedicalMember
2024-06-29
2024-09-27
0001076930
novt:ThomasNSecorMember
2025-09-26
0001076930
novt:UnallocatedMember
novt:FiscalYearTwentyTwentyFourMember
2024-06-29
2024-09-27
0001076930
us-gaap:FairValueInputsLevel2Member
us-gaap:FairValueMeasurementsRecurringMember
novt:AccruedExpensesAndOtherCurrentLiabilitiesMember
2025-09-26
0001076930
novt:MedicalSolutionsMember
us-gaap:OperatingSegmentsMember
2024-01-01
2024-09-27
0001076930
us-gaap:RetainedEarningsMember
2025-09-26
0001076930
novt:MedicalSolutionsMember
2024-01-01
2024-09-27
0001076930
novt:TwoThousandTwentyCommonStockRepurchasePlanMember
2025-01-01
2025-09-26
0001076930
srt:MaximumMember
novt:ProfessionalServicesMember
2025-01-01
2025-09-26
0001076930
novt:RestOfAsiaPacificMember
2025-01-01
2025-09-26
0001076930
us-gaap:ForeignExchangeForwardMember
2024-01-01
2024-12-31
0001076930
novt:TwoThousandTwentyCommonStockRepurchasePlanMember
2020-02-29
0001076930
novt:EmployeeRelatedMember
2025-01-01
2025-09-26
0001076930
us-gaap:FairValueMeasurementsRecurringMember
2024-12-31
0001076930
novt:AttainmentBasedPsusAndHybridPsusMember
2024-06-29
2024-09-27
0001076930
novt:FiscalYearTwentyTwentyMember
2024-01-01
2024-09-27
0001076930
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember
2024-12-31
0001076930
us-gaap:CostOfSalesMember
2024-01-01
2024-09-27
0001076930
2023-12-31
0001076930
novt:RestOfEuropeMember
2024-06-29
2024-09-27
0001076930
us-gaap:FairValueInputsLevel3Member
us-gaap:FairValueMeasurementsRecurringMember
novt:AccruedExpensesAndOtherCurrentLiabilitiesMember
2025-09-26
0001076930
novt:MedicalSolutionsMember
2025-01-01
2025-09-26
0001076930
novt:TermLoanMember
2025-09-26
0001076930
us-gaap:MaterialReconcilingItemsMember
2025-01-01
2025-09-26
0001076930
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-06-27
0001076930
novt:AutomationEnablingTechnologiesMember
2024-12-31
0001076930
us-gaap:RetainedEarningsMember
2023-12-31
0001076930
novt:RestOfAsiaPacificMember
2025-06-28
2025-09-26
0001076930
novt:KeonnTechnologiesSLMember
2025-04-08
2025-09-26
0001076930
novt:OtherCountriesMember
2025-01-01
2025-09-26
0001076930
novt:OtherCountriesMember
2024-01-01
2024-09-27
0001076930
novt:FiscalYearTwentyTwentyFiveMember
2025-01-01
2025-09-26
0001076930
us-gaap:PerformanceSharesMember
novt:EquityIncentivePlanTwentyTenMember
2025-01-01
2025-09-26
0001076930
novt:MedicalMember
2025-01-01
2025-09-26
0001076930
2025-06-27
0001076930
us-gaap:OperatingSegmentsMember
2024-01-01
2024-09-27
0001076930
novt:FiscalYearTwentyTwentyFourMember
novt:AutomationEnablingTechnologiesMember
2025-01-01
2025-09-26
0001076930
novt:FiscalYearTwentyTwentyMember
2025-06-28
2025-09-26
0001076930
novt:MedicalSolutionsMember
novt:FiscalYearTwentyTwentyFiveMember
2024-06-29
2024-09-27
0001076930
novt:FourthAmendedAndRestatedCreditAgreementMember
2025-06-27
0001076930
2025-10-27
0001076930
us-gaap:CustomerRelationshipsMember
2025-09-26
0001076930
us-gaap:FairValueInputsLevel2Member
us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
2025-09-26
0001076930
novt:FourthAmendedAndRestatedCreditAgreementMember
novt:EuroTermLoanFacilityBeginningInSeptemberTwoThousandTwentyFiveMember
2025-06-27
2025-06-27
0001076930
novt:RestOfEuropeMember
2025-01-01
2025-09-26
0001076930
novt:AutomationEnablingTechnologiesMember
novt:PrecisionManufacturingMember
2025-06-28
2025-09-26
0001076930
us-gaap:OperatingSegmentsMember
2025-01-01
2025-09-26
0001076930
us-gaap:FacilityClosingMember
2024-12-31
0001076930
2024-06-29
2024-09-27
0001076930
novt:MedicalSolutionsMember
novt:FiscalYearTwentyTwentyFiveMember
2025-06-28
2025-09-26
0001076930
us-gaap:FairValueInputsLevel3Member
us-gaap:FairValueMeasurementsRecurringMember
2024-12-31
0001076930
novt:FourthAmendedAndRestatedCreditAgreementMember
us-gaap:RevolvingCreditFacilityMember
2025-06-27
2025-06-27
0001076930
us-gaap:TrademarksAndTradeNamesMember
2024-12-31
0001076930
us-gaap:RetainedEarningsMember
2024-06-28
0001076930
us-gaap:FairValueInputsLevel2Member
us-gaap:FairValueMeasurementsRecurringMember
2024-12-31
0001076930
novt:MedicalMember
2024-01-01
2024-09-27
0001076930
novt:FiscalYearTwentyTwentyFiveMember
2025-06-28
2025-09-26
0001076930
novt:MedicalSolutionsMember
us-gaap:OperatingSegmentsMember
2024-06-29
2024-09-27
0001076930
srt:MaximumMember
2025-01-01
2025-09-26
0001076930
us-gaap:OtherRestructuringMember
2024-12-31
0001076930
us-gaap:AdditionalPaidInCapitalMember
2024-06-28
0001076930
country:DE
2025-06-28
2025-09-26
0001076930
novt:FiscalYearTwentyTwentyFiveMember
novt:AutomationEnablingTechnologiesMember
2024-01-01
2024-09-27
0001076930
us-gaap:RetainedEarningsMember
2024-09-27
0001076930
novt:MedicalSolutionsMember
novt:AdvancedSurgeryMember
2024-06-29
2024-09-27
0001076930
srt:DirectorMember
novt:RestrictedStockUnitsAndDeferredStockUnitsMember
novt:EquityIncentivePlanTwentyTenMember
us-gaap:SellingGeneralAndAdministrativeExpensesMember
2024-01-01
2024-09-27
0001076930
us-gaap:RevolvingCreditFacilityMember
2024-12-31
0001076930
us-gaap:ForeignExchangeForwardMember
srt:MaximumMember
2025-01-01
2025-09-26
0001076930
2024-12-31
0001076930
novt:MedicalSolutionsMember
novt:PrecisionMedicineMember
2025-06-28
2025-09-26
0001076930
novt:AdvancedIndustrialMember
2025-01-01
2025-09-26
0001076930
novt:HybridPsusMember
novt:EquityIncentivePlanTwentyTenMember
srt:MaximumMember
2025-01-01
2025-09-26
0001076930
2021-05-31
0001076930
country:US
2024-01-01
2024-09-27
0001076930
novt:TermLoanMember
novt:FourthAmendedAndRestatedCreditAgreementMember
2025-06-27
0001076930
country:US
2025-06-28
2025-09-26
0001076930
novt:ProfessionalAndConsultingFeesMember
2025-06-28
2025-09-26
0001076930
novt:EquityIncentivePlanTwentyTenMember
srt:MinimumMember
novt:MarketBasedPsusMember
2025-01-01
2025-09-26
0001076930
novt:FiscalYearTwentyTwentyFiveMember
novt:AutomationEnablingTechnologiesMember
2025-01-01
2025-09-26
0001076930
novt:EquityIncentivePlanTwentyTenMember
us-gaap:EmployeeStockOptionMember
2025-09-26
0001076930
us-gaap:CommonStockMember
2024-09-27
0001076930
srt:MinimumMember
novt:KeonnTechnologiesSLMember
2025-04-08
2025-04-08
0001076930
us-gaap:ResearchAndDevelopmentExpenseMember
2024-01-01
2024-09-27
0001076930
us-gaap:OtherRestructuringMember
2025-01-01
2025-09-26
0001076930
us-gaap:CostOfSalesMember
2024-06-29
2024-09-27
0001076930
country:DE
2024-06-29
2024-09-27
0001076930
novt:FourthAmendedAndRestatedCreditAgreementMember
us-gaap:RevolvingCreditFacilityMember
2025-06-27
0001076930
us-gaap:WarrantyObligationsMember
2025-01-01
2025-09-26
0001076930
novt:TermLoanAndRevolvingCreditFacilityMember
2025-09-26
0001076930
novt:TermLoanAndRevolvingCreditFacilityMember
2024-12-31
0001076930
novt:KeonnTechnologiesSLMember
srt:MaximumMember
2025-04-08
2025-04-08
0001076930
2025-09-26
0001076930
us-gaap:FairValueInputsLevel3Member
novt:KeonnTechnologiesSLMember
2025-09-26
0001076930
novt:FiscalYearTwentyTwentyFiveMember
novt:AutomationEnablingTechnologiesMember
2024-06-29
2024-09-27
0001076930
novt:FiscalYearTwentyTwentyFourMember
2024-06-29
2024-09-27
0001076930
novt:FiscalYearTwentyTwentyFiveMember
2024-06-29
2024-09-27
0001076930
novt:AttainmentBasedPsusAndHybridPsusMember
2025-06-28
2025-09-26
0001076930
novt:KeonnTechnologiesSLMember
us-gaap:TradeNamesMember
2025-04-08
0001076930
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-12-31
0001076930
novt:FourthAmendedAndRestatedCreditAgreementMember
novt:EuroTermLoansMember
2025-06-27
0001076930
novt:FiscalYearTwentyTwentyMember
2025-09-26
0001076930
novt:MedicalSolutionsMember
novt:AdvancedSurgeryMember
2025-06-28
2025-09-26
0001076930
novt:EquityIncentivePlanTwentyTenMember
us-gaap:EmployeeStockOptionMember
2025-01-01
2025-09-26
0001076930
country:DE
2024-01-01
2024-09-27
0001076930
novt:FiscalYearTwentyTwentyMember
2024-06-29
2024-09-27
0001076930
novt:MedicalSolutionsMember
novt:PrecisionMedicineMember
2025-01-01
2025-09-26
0001076930
novt:RestOfAsiaPacificMember
2024-06-29
2024-09-27
0001076930
novt:FiscalYearTwentyTwentyFourMember
srt:MaximumMember
2025-09-26
0001076930
novt:KeonnTechnologiesSLMember
2025-06-28
2025-09-26
0001076930
us-gaap:CostOfSalesMember
2025-06-28
2025-09-26
0001076930
novt:AutomationEnablingTechnologiesMember
novt:RoboticsAndAutomationMember
2024-01-01
2024-09-27
0001076930
novt:MedicalSolutionsMember
novt:AdvancedSurgeryMember
2024-01-01
2024-09-27
0001076930
us-gaap:FairValueInputsLevel3Member
us-gaap:FairValueMeasurementsRecurringMember
novt:AccruedExpensesAndOtherCurrentLiabilitiesMember
2024-12-31
0001076930
novt:FiscalYearTwentyTwentyFourMember
novt:AutomationEnablingTechnologiesMember
2024-01-01
2024-09-27
0001076930
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-06-29
2024-09-27
0001076930
novt:FacilitySaleMember
2025-01-01
2025-09-26
0001076930
us-gaap:AdditionalPaidInCapitalMember
2024-01-01
2024-09-27
0001076930
novt:KeonnTechnologiesSLMember
us-gaap:CustomerRelationshipsMember
2025-04-08
2025-04-08
0001076930
novt:AttainmentBasedPsusAndHybridPsusMember
2024-01-01
2024-09-27
0001076930
us-gaap:ResearchAndDevelopmentExpenseMember
2024-06-29
2024-09-27
0001076930
novt:UnallocatedMember
novt:FiscalYearTwentyTwentyFiveMember
2025-06-28
2025-09-26
0001076930
us-gaap:CommonStockMember
2024-12-31
0001076930
us-gaap:FairValueInputsLevel2Member
us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
2024-12-31
0001076930
novt:FiscalYearTwentyTwentyFourMember
2025-01-01
2025-09-26
0001076930
novt:AutomationEnablingTechnologiesMember
novt:PrecisionManufacturingMember
2025-01-01
2025-09-26
0001076930
novt:FiscalYearTwentyTwentyFiveMember
2024-01-01
2024-09-27
0001076930
us-gaap:RetainedEarningsMember
2025-06-27
0001076930
us-gaap:ResearchAndDevelopmentExpenseMember
2025-01-01
2025-09-26
0001076930
novt:OtherCountriesMember
2025-06-28
2025-09-26
0001076930
novt:KeonnTechnologiesSLMember
us-gaap:CustomerRelationshipsMember
2025-04-08
0001076930
novt:AutomationEnablingTechnologiesMember
2025-06-28
2025-09-26
0001076930
novt:AutomationEnablingTechnologiesMember
novt:PrecisionManufacturingMember
2024-06-29
2024-09-27
0001076930
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-09-26
0001076930
novt:UnallocatedMember
novt:FiscalYearTwentyTwentyFourMember
2025-01-01
2025-09-26
0001076930
novt:RestOfAsiaPacificMember
2024-01-01
2024-09-27
0001076930
us-gaap:OperatingSegmentsMember
novt:AutomationEnablingTechnologiesMember
2025-01-01
2025-09-26
0001076930
us-gaap:CommonStockMember
2025-06-27
0001076930
novt:KeonnTechnologiesSLMember
us-gaap:DevelopedTechnologyRightsMember
2025-04-08
0001076930
us-gaap:RestrictedStockUnitsRSUMember
novt:EquityIncentivePlanTwentyTenMember
2024-12-31
0001076930
us-gaap:DevelopedTechnologyRightsMember
novt:KeonnTechnologiesSLMember
2025-04-08
2025-04-08
0001076930
novt:FiscalYearTwentyTwentyFiveMember
2025-09-26
0001076930
novt:RestOfEuropeMember
2025-06-28
2025-09-26
0001076930
us-gaap:TrademarksAndTradeNamesMember
2025-09-26
0001076930
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-09-27
0001076930
us-gaap:CorporateNonSegmentMember
2024-01-01
2024-09-27
0001076930
novt:ProfessionalAndConsultingFeesMember
2024-06-29
2024-09-27
0001076930
us-gaap:AdditionalPaidInCapitalMember
2024-06-29
2024-09-27
0001076930
us-gaap:FairValueInputsLevel3Member
novt:KeonnTechnologiesSLMember
2025-01-01
2025-09-26
0001076930
us-gaap:ForeignCurrencyGainLossMember
us-gaap:ForeignExchangeForwardMember
2024-01-01
2024-09-27
0001076930
novt:FourthAmendedAndRestatedCreditAgreementMember
novt:TermLoanMember
2025-06-27
2025-06-27
0001076930
novt:ProfessionalAndConsultingFeesMember
2025-01-01
2025-09-26
0001076930
novt:MedicalSolutionsMember
2024-12-31
0001076930
novt:KeonnTechnologiesSLMember
2025-01-01
2025-09-26
0001076930
novt:MatthijsGlastraMember
2025-09-26
0001076930
novt:AdvancedIndustrialMember
2024-01-01
2024-09-27
0001076930
2024-06-28
0001076930
us-gaap:RetainedEarningsMember
2025-06-28
2025-09-26
0001076930
novt:MedicalSolutionsMember
novt:PrecisionMedicineMember
2024-01-01
2024-09-27
0001076930
us-gaap:ForeignExchangeForwardMember
2025-09-26
0001076930
novt:MedicalSolutionsMember
novt:FiscalYearTwentyTwentyFourMember
2025-06-28
2025-09-26
0001076930
country:CN
2025-06-28
2025-09-26
0001076930
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-12-31
0001076930
srt:MinimumMember
2025-01-01
2025-09-26
0001076930
2024-01-01
2024-12-31
0001076930
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember
2025-09-26
0001076930
novt:MedicalSolutionsMember
2025-09-26
0001076930
novt:UnallocatedMember
novt:FiscalYearTwentyTwentyFiveMember
2025-01-01
2025-09-26
0001076930
us-gaap:RestrictedStockUnitsRSUMember
novt:EquityIncentivePlanTwentyTenMember
srt:MinimumMember
2025-01-01
2025-09-26
0001076930
novt:AutomationEnablingTechnologiesMember
2025-09-26
0001076930
novt:SeveranceFacilityRelatedAndOtherChargesMember
novt:FiscalYearTwentyTwentyFiveMember
2025-06-28
2025-09-26
0001076930
novt:EquityIncentivePlanTwentyTenMember
srt:MaximumMember
novt:MarketBasedPsusMember
2025-01-01
2025-09-26
0001076930
us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember
us-gaap:FairValueMeasurementsRecurringMember
2024-12-31
0001076930
us-gaap:AdditionalPaidInCapitalMember
2024-12-31
0001076930
us-gaap:CorporateNonSegmentMember
2025-06-28
2025-09-26
0001076930
us-gaap:FacilityClosingMember
2025-01-01
2025-09-26
0001076930
us-gaap:RetainedEarningsMember
2024-01-01
2024-09-27
0001076930
us-gaap:FairValueInputsLevel2Member
us-gaap:FairValueMeasurementsRecurringMember
2025-09-26
0001076930
us-gaap:AdditionalPaidInCapitalMember
2023-12-31
0001076930
novt:MedicalSolutionsMember
novt:AdvancedSurgeryMember
2025-01-01
2025-09-26
0001076930
us-gaap:CanadaRevenueAgencyMember
country:CA
2025-01-01
2025-09-26
0001076930
novt:SeveranceFacilityRelatedAndOtherChargesMember
novt:FiscalYearTwentyTwentyFiveMember
2025-01-01
2025-09-26
0001076930
us-gaap:FairValueInputsLevel3Member
2025-01-01
2025-09-26
0001076930
novt:AutomationEnablingTechnologiesMember
novt:PrecisionManufacturingMember
2024-01-01
2024-09-27
0001076930
2025-03-29
2025-06-27
0001076930
novt:FacilitySaleMember
2025-09-26
0001076930
us-gaap:FairValueInputsLevel2Member
us-gaap:FairValueMeasurementsRecurringMember
novt:AccruedExpensesAndOtherCurrentLiabilitiesMember
2024-12-31
0001076930
novt:HybridPsusMember
2025-09-26
0001076930
us-gaap:FairValueInputsLevel3Member
us-gaap:FairValueMeasurementsRecurringMember
2025-09-26
0001076930
us-gaap:CustomerRelationshipsMember
2024-12-31
0001076930
novt:FiscalYearTwentyTwentyFourMember
srt:MinimumMember
2025-09-26
0001076930
us-gaap:PerformanceSharesMember
novt:EquityIncentivePlanTwentyTenMember
2025-09-26
0001076930
us-gaap:RestrictedStockUnitsRSUMember
novt:EquityIncentivePlanTwentyTenMember
2025-09-26
0001076930
us-gaap:CorporateNonSegmentMember
2024-06-29
2024-09-27
0001076930
novt:FiscalYearTwentyTwentyMember
2025-01-01
2025-09-26
0001076930
novt:FiscalYearTwentyTwentyFourMember
2025-06-28
2025-09-26
0001076930
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2025-06-28
2025-09-26
0001076930
srt:MaximumMember
2025-09-26
0001076930
us-gaap:CommonStockMember
2023-12-31
0001076930
us-gaap:CommonStockMember
2025-01-01
2025-09-26
0001076930
country:US
2024-06-29
2024-09-27
0001076930
novt:AutomationEnablingTechnologiesMember
2025-01-01
2025-09-26
0001076930
novt:UnallocatedMember
novt:FiscalYearTwentyTwentyFiveMember
2024-06-29
2024-09-27
0001076930
novt:EmployeeRelatedMember
2025-09-26
0001076930
2025-06-28
2025-09-26
0001076930
us-gaap:ForeignExchangeForwardMember
2024-12-31
0001076930
us-gaap:RestrictedStockUnitsRSUMember
novt:EquityIncentivePlanTwentyTenMember
2025-01-01
2025-09-26
0001076930
us-gaap:FairValueMeasurementsRecurringMember
novt:AccruedExpensesAndOtherCurrentLiabilitiesMember
2024-12-31
0001076930
novt:TwoThousandTwentyFiveCommonStockRepurchasePlanMember
2025-09-30
0001076930
2024-01-01
2024-09-27
0001076930
us-gaap:OperatingSegmentsMember
novt:AutomationEnablingTechnologiesMember
2024-01-01
2024-09-27
0001076930
us-gaap:RestrictedStockUnitsRSUMember
novt:EquityIncentivePlanTwentyTenMember
srt:MaximumMember
2025-01-01
2025-09-26
0001076930
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-01-01
2024-09-27
0001076930
country:CN
2024-01-01
2024-09-27
0001076930
us-gaap:FairValueMeasurementsRecurringMember
2025-09-26
0001076930
novt:HybridPsusMember
2025-01-01
2025-09-26
0001076930
us-gaap:MaterialReconcilingItemsMember
2024-06-29
2024-09-27
0001076930
novt:UnallocatedMember
novt:FiscalYearTwentyTwentyFiveMember
2024-01-01
2024-09-27
0001076930
novt:FourthAmendedAndRestatedCreditAgreementMember
novt:USTermLoanFacilityBeginningInSeptemberTwoThousandTwentySevenMember
2025-06-27
2025-06-27
0001076930
us-gaap:TechnologyBasedIntangibleAssetsMember
2025-09-26
0001076930
us-gaap:OperatingSegmentsMember
2024-06-29
2024-09-27
0001076930
us-gaap:FairValueInputsLevel3Member
2025-09-26
0001076930
novt:MedicalMember
2025-06-28
2025-09-26
0001076930
us-gaap:SellingGeneralAndAdministrativeExpensesMember
2024-01-01
2024-09-27
0001076930
novt:TermLoanMember
novt:FourthAmendedAndRestatedCreditAgreementMember
2025-01-01
2025-09-26
0001076930
novt:MedicalSolutionsMember
novt:FiscalYearTwentyTwentyFourMember
2024-06-29
2024-09-27
0001076930
us-gaap:CanadaRevenueAgencyMember
country:CA
2024-01-01
2024-09-27
0001076930
us-gaap:AdditionalPaidInCapitalMember
2025-01-01
2025-09-26
0001076930
srt:MinimumMember
us-gaap:WarrantyObligationsMember
2025-01-01
2025-09-26
0001076930
2025-01-01
2025-09-26
0001076930
us-gaap:FacilityClosingMember
2025-09-26
0001076930
us-gaap:AdditionalPaidInCapitalMember
2025-09-26
0001076930
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember
2025-01-01
2025-09-26
0001076930
novt:EmployeeRelatedMember
2024-12-31
0001076930
novt:AdvancedIndustrialMember
2025-06-28
2025-09-26
0001076930
us-gaap:AdditionalPaidInCapitalMember
2025-06-27
0001076930
us-gaap:OtherRestructuringMember
2025-09-26
0001076930
novt:FiscalYearTwentyTwentyFourMember
novt:AutomationEnablingTechnologiesMember
2025-06-28
2025-09-26
0001076930
us-gaap:ForeignCurrencyGainLossMember
us-gaap:ForeignExchangeForwardMember
2025-06-28
2025-09-26
0001076930
novt:FourthAmendedAndRestatedCreditAgreementMember
us-gaap:RevolvingCreditFacilityMember
2025-01-01
2025-09-26
0001076930
novt:MedicalSolutionsMember
novt:FiscalYearTwentyTwentyFourMember
2024-01-01
2024-09-27
0001076930
us-gaap:FairValueInputsLevel3Member
2024-12-31
0001076930
novt:FiscalYearTwentyTwentyMember
2025-01-01
2025-01-31
0001076930
novt:SeveranceFacilityRelatedAndOtherChargesMember
novt:FiscalYearTwentyTwentyFourMember
2025-01-01
2025-09-26
0001076930
us-gaap:PerformanceSharesMember
novt:EquityIncentivePlanTwentyTenMember
2024-12-31
0001076930
novt:FiscalYearTwentyTwentyFourMember
2024-01-01
2024-09-27
0001076930
us-gaap:CommonStockMember
2025-06-28
2025-09-26
0001076930
novt:UnallocatedMember
novt:FiscalYearTwentyTwentyFourMember
2024-01-01
2024-09-27
0001076930
novt:AutomationEnablingTechnologiesMember
novt:RoboticsAndAutomationMember
2025-01-01
2025-09-26
0001076930
novt:MedicalSolutionsMember
2025-06-28
2025-09-26
0001076930
novt:MedicalSolutionsMember
us-gaap:OperatingSegmentsMember
2025-06-28
2025-09-26
0001076930
novt:MatthijsGlastraMember
2025-06-28
2025-09-26
0001076930
novt:TwoThousandTwentyCommonStockRepurchasePlanMember
2025-09-26
0001076930
novt:MotionSolutionsParentCorpMember
2024-01-01
2024-09-27
0001076930
novt:MedicalSolutionsMember
novt:FiscalYearTwentyTwentyFiveMember
2025-01-01
2025-09-26
0001076930
novt:OtherCountriesMember
2024-06-29
2024-09-27
0001076930
novt:AttainmentBasedPsusMember
novt:EquityIncentivePlanTwentyTenMember
srt:MinimumMember
2025-01-01
2025-09-26
0001076930
2021-05-01
2021-05-31
0001076930
novt:MedicalSolutionsMember
novt:FiscalYearTwentyTwentyFiveMember
2024-01-01
2024-09-27
0001076930
srt:MaximumMember
us-gaap:LandMember
2025-01-01
2025-09-26
iso4217:EUR
iso4217:USD
xbrli:shares
xbrli:pure
novt:EndMarket
xbrli:shares
novt:Segment
iso4217:USD

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 
10-Q

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended 
September 26, 
2025

Or

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File No.: 
001-35083

NOVANTA INC.
(Exact name of registrant as specified in its charter)

New Brunswick, Canada

98-0110412

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

125 Middlesex Turnpike
, 
Bedford
, 
Massachusetts
, 
USA

01730

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (
781
) 
266-5700

N/A

 (Former name, former address and former fiscal year, if changed since last report) 	

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common shares, no par value

NOVT

The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    
Yes

☒

No

☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    
Yes

☒

No

☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☒

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    
☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    
Yes

☐

No

☒

As of October 27, 2025
, there were 
35,775,123
 of the Registrant’s common shares, no par value, issued and outstanding.

NOVANTA INC.
TABLE OF CONTENTS

Item No.

Page
No.

PART I — FINANCIAL INFORMATION

1

ITEM 1.

FINANCIAL STATEMENTS

1

CONSOLIDATED BALANCE SHEETS (unaudited)

1

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited)

3

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (unaudited)

4

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

5

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

6

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

30

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

41

ITEM 4.

CONTROLS AND PROCEDURES

41

PART II — OTHER INFORMATION

42

ITEM 1.

LEGAL PROCEEDINGS

42

ITEM 1A.

RISK FACTORS

42

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

43

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

43

ITEM 4.

MINE SAFETY DISCLOSURES

43

ITEM 5.

OTHER INFORMATION

43

ITEM 6.

EXHIBITS

45

SIGNATURES

46

P
ART I—FINANCIAL INFORMATION

I
tem 1. Financial Statements
NOVANTA INC.

C
ONSOLIDATED BALANCE SHEETS

(In thousands of U.S. dollars or shares)

(Unaudited)

September 26,

December 31,

2025

2024

ASSETS

Current assets

Cash and cash equivalents

$

89,221

$

113,989

Accounts receivable, net of allowance of $
997
 and $
505
, respectively

170,563

151,026

Inventories

179,977

144,606

Prepaid income taxes and income taxes receivable

9,755

8,076

Prepaid expenses and other current assets

18,903

15,951

Total current assets

468,419

433,648

Property, plant and equipment, net

119,773

113,135

Operating lease assets

43,283

42,908

Deferred tax assets

27,088

22,887

Other assets

6,487

5,991

Intangible assets, net

193,248

185,844

Goodwill

647,513

584,098

Total assets

$

1,505,811

$

1,388,511

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities

Current portion of long-term debt

$

5,685

$

4,691

Accounts payable

100,210

76,890

Income taxes payable

4,007

16,000

Current portion of operating lease liabilities

10,165

9,879

Accrued expenses and other current liabilities

66,793

60,331

Total current liabilities

186,860

167,791

Long-term debt

445,658

411,949

Operating lease liabilities

40,407

40,548

Deferred tax liabilities

19,703

13,093

Income taxes payable

5,221

4,941

Other liabilities

6,486

4,491

Total liabilities

704,335

642,813

Commitments and contingencies (Note 15)

Stockholders’ equity:

Preferred shares, 
no
 par value; Authorized shares: 
7,000
;

No
 shares issued and outstanding

—

—

Common shares, 
no
 par value; Authorized shares: 
unlimited
;
   Issued and outstanding: 
35,846
 and 
35,938
, respectively

423,856

423,856

Additional paid-in capital

76,499

84,214

Retained earnings

303,907

267,549

Accumulated other comprehensive loss

(
2,786

)

(
29,921

)

Total stockholders' equity

801,476

745,698

Total liabilities and stockholders’ equity

$

1,505,811

$

1,388,511

The accompanying notes are an integral part of these consolidated financial statements.

1

NOVANTA INC.

C
ONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands of U.S. dollars or shares, except per share amounts)

(Unaudited)

Three

Months Ended

Nine Months Ended

September 26,

September 27,

September 26,

September 27,

2025

2024

2025

2024

Revenue

$

247,836

$

244,405

$

722,251

$

711,185

Cost of revenue

136,915

135,190

400,230

397,865

Gross profit

110,921

109,215

322,021

313,320

Operating expenses:

Research and development and engineering

24,090

23,253

72,617

70,230

Selling, general and administrative

51,378

44,319

144,077

132,642

Amortization of purchased intangible assets

6,928

6,589

19,353

19,246

Restructuring, acquisition, and related costs

6,677

2,499

16,794

7,325

Total operating expenses

89,073

76,660

252,841

229,443

Operating income

21,848

32,555

69,180

83,877

Interest income (expense), net

(
6,014

)

(
8,079

)

(
17,473

)

(
24,599

)

Foreign exchange transaction gains (losses), net

14

(
202

)

(
3,098

)

(
787

)

Other income (expense), net

(
90

)

(
49

)

(
644

)

(
220

)

Income before income taxes

15,758

24,225

47,965

58,271

Income tax provision

5,105

5,033

11,607

10,648

Net income

$

10,653

$

19,192

$

36,358

$

47,623

Earnings per common share (Note 5):

Basic

$

0.30

$

0.53

$

1.01

$

1.33

Diluted

$

0.30

$

0.53

$

1.01

$

1.32

Weighted average common shares outstanding—basic

35,967

35,959

36,004

35,940

Weighted average common shares outstanding—diluted

36,040

36,129

36,082

36,116

The accompanying notes are an integral part of these consolidated financial statements.

2

NOVANTA INC.
C
ONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands of U.S. dollars)

(Unaudited)

Three

Months Ended

Nine Months Ended

September 26,

September 27,

September 26,

September 27,

2025

2024

2025

2024

Net income

$

10,653

$

19,192

$

36,358

$

47,623

Other comprehensive income (loss):

Foreign currency translation adjustments, net of tax
 (1)

(
1,997

)

14,869

26,960

11,053

Pension liability adjustments, net of tax 
(2)

343

(
159

)

175

311

Total other comprehensive income (loss)

(
1,654

)

14,710

27,135

11,364

Total consolidated comprehensive income

$

8,999

$

33,902

$

63,493

$

58,987

(1)
The tax effect on this component of comprehensive income (los
s) was nominal for all periods presented.
(2)
The tax effect on this component of comprehensive income (loss) was nominal for all
 periods presented. See Note 4 to the Consolidated Financial Statements for the total amount of pension liability adjustments reclassified out of accumulated other comprehensive income (loss).

The accompanying notes are an integral part of these consolidated financial statements.

3

NOVANTA INC.
CONSOLIDATED STATEME
NTS OF STOCKHOLDERS’ EQUITY

(In thousands of U.S. dollars or shares)

(Unaudited)

Common Shares

Additional Paid-In

Retained

Accumulated Other

#

of

Shares

Amount

Capital

Earnings

Comprehensive Loss

Total

Three Months Ended September 26, 2025

Balance at June 27, 2025

35,973

$

423,856

$

85,468

$

293,254

$

(
1,132

)

$

801,446

Net income

—

—

—

10,653

—

10,653

Common shares issued under stock plans

11

—

—

—

—

—

Common shares withheld for taxes on vested stock awards

(
5

)

—

(
533

)

—

—

(
533

)

Repurchases of common shares

(
133

)

—

(
15,134

)

—

—

(
15,134

)

Share-based compensation

—

—

6,698

—

—

6,698

Other comprehensive income (loss), net of tax

—

—

—

—

(
1,654

)

(
1,654

)

Balance at September 26, 2025

35,846

$

423,856

$

76,499

$

303,907

$

(
2,786

)

$

801,476

Nine Months Ended September 26, 2025

Balance at December 31, 2024

35,938

$

423,856

$

84,214

$

267,549

$

(
29,921

)

$

745,698

Net income

—

—

—

36,358

—

36,358

Common shares issued under stock plans

143

—

—

—

—

—

Common shares withheld for taxes on vested stock awards

(
56

)

—

(
7,720

)

—

—

(
7,720

)

Repurchases of common shares

(
179

)

—

(
21,291

)

—

—

(
21,291

)

Share-based compensation

—

—

21,296

—

—

21,296

Other comprehensive income (loss), net of tax

—

—

—

—

27,135

27,135

Balance at September 26, 2025

35,846

$

423,856

$

76,499

$

303,907

$

(
2,786

)

$

801,476

Three Months Ended September 27, 2024

Balance at June 28, 2024

35,895

$

423,856

$

73,627

$

231,893

$

(
27,384

)

$

701,992

Net income

—

—

—

19,192

—

19,192

Common shares issued under stock plans

23

—

—

—

—

—

Common shares withheld for taxes on vested stock awards

(
2

)

—

(
63

)

—

—

(
63

)

Share-based compensation

—

—

6,364

—

—

6,364

Other comprehensive income (loss), net of tax

—

—

—

—

14,710

14,710

Balance at September 27, 2024

35,916

$

423,856

$

79,928

$

251,085

$

(
12,674

)

$

742,195

Nine Months Ended September 27, 2024

Balance at December 31, 2023

35,814

$

423,856

$

70,180

$

203,462

$

(
24,038

)

$

673,460

Net income

—

—

—

47,623

—

47,623

Common shares issued under stock plans

159

—

—

—

—

—

Common shares withheld for taxes on vested stock awards

(
57

)

—

(
8,924

)

—

—

(
8,924

)

Share-based compensation

—

—

18,672

—

—

18,672

Other comprehensive income (loss), net of tax

—

—

—

—

11,364

11,364

Balance at September 27, 2024

35,916

$

423,856

$

79,928

$

251,085

$

(
12,674

)

$

742,195

The accompanying notes are an integral part of these consolidated financial statements.

4

NOVANTA INC.

C
ONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands of U.S. dollars)

(Unaudited)

Nine Months Ended

September 26,

September 27,

2025

2024

Cash flows from operating activities:

Net income

$

36,358

$

47,623

Adjustments to reconcile net income to
   net cash provided by operating activities:

Depreciation and amortization

44,855

41,200

Provision for inventory excess and obsolescence

2,677

7,325

Share-based compensation

21,296

18,672

Deferred income taxes

(
6,444

)

(
11,908

)

Write-off of unamortized deferred financing costs

426

—

Inventory acquisition fair value adjustments

—

2,777

Loss (gain) on disposal of fixed assets

(
4,087

)

—

Other

1,368

1,273

Changes in assets and liabilities which (used)/provided cash, excluding
   effects from business acquisitions:

Accounts receivable

(
12,426

)

(
16,087

)

Inventories

(
27,312

)

416

Prepaid income taxes, income taxes receivable, prepaid expenses
     and other current assets

(
2,568

)

(
2,378

)

Accounts payable, income taxes payable, accrued expenses
     and other current liabilities

(
3

)

7,506

Other non-current assets and liabilities

1,111

531

Net cash provided by operating activities

55,251

96,950

Cash flows from investing activities:

Cash paid for business acquisitions, net of working capital adjustments

(
64,291

)

(
191,200

)

Purchases of property, plant and equipment

(
11,955

)

(
14,913

)

Proceeds from sale of property, plant and equipment

5,537

—

Net cash used in investing activities

(
70,709

)

(
206,113

)

Cash flows from financing activities:

Borrowings under revolving credit facilities

72,805

198,000

Repayments under term loan and revolving credit facilities

(
49,205

)

(
95,983

)

Payments of debt issuance costs

(
3,843

)

—

Payments of withholding taxes from share-based awards

(
7,720

)

(
8,924

)

Repurchases of common shares

(
20,213

)

—

Other financing activities

(
3,143

)

(
534

)

Net cash (used in) provided by financing activities

(
11,319

)

92,559

Effect of exchange rates on cash and cash equivalents

2,009

4,243

Decrease in cash and cash equivalents

(
24,768

)

(
12,361

)

Cash and cash equivalents, beginning of the period

113,989

105,051

Cash and cash equivalents, end of the period

$

89,221

$

92,690

Supplemental disclosure of cash flow information:

Cash paid for interest

$

17,879

$

25,376

Cash paid for income taxes

$

31,306

$

18,807

Income tax refunds received

$

540

$

1,069

The accompanying notes are an integral part of these consolidated financial statements.

5

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025
(Unaudited)

1. Basis of Presentation

Novanta Inc. (collectively with its subsidiaries, referred to as “Novanta”, the “Company”, “we”, “us”, “our”) is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers (“OEMs”) a competitive advantage. Novanta combines deep proprietary technology expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and advanced surgery with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to the customers' demanding applications.
The accompanying unaudited interim consolidated financial statements have been prepared by the Company in United States (“U.S.”) dollars and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”), the instructions to Form 10-Q and the provisions of Regulation S-X pertaining to interim financial statements. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the U.S. have been condensed or omitted. The interim consolidated financial statements and notes included in this report should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. In the opinion of management, these interim consolidated financial statements include all adjustments and accruals of a normal and recurring nature necessary to fairly state the results of the interim periods presented. The results for interim periods are not necessarily indicative of results to be expected for the full year or for any future periods.

The Company’s unaudited interim consolidated financial statements are prepared for each quarterly period ending on the Friday closest to the end of the calendar quarter, with the exception of the fourth quarter which always ends on December 31.
Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Estimates and assumptions are reviewed on an on-going basis and the effects of revisions are reflected in the period in which such revisions are deemed to be necessary. The Company evaluates its estimates based on historical experience, current conditions, and various other assumptions that it believes are reasonable under the circumstances. Actual results could differ significantly from these estimates.
Recent Accounting Pronouncements

The following table provides a brief description of recent Accounting Standards Updates (“ASU”) issued by the Financial Accounting Standards Board (“FASB”):

Standard

Description

Effective Date

Effect on the Financial Statements or Other Significant Matters

In October 2023, the FASB issued ASU 2023-06, “Disclosure Improvements: Codification Amendments in Response to SEC’s Disclosure Update and Simplification Initiative.”

ASU 2023-06 clarifies or improves disclosure and presentation requirements of a variety of topics, which allow users to easily compare entities subject to the SEC’s existing disclosure requirements with those entities that were not previously subject to such requirements and align the requirements in the FASB Accounting Standards Codification with the SEC’s regulations.

The effective date for each amendment in ASU 2023-06 will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited.

The Company is currently evaluating the impact of ASU 2023-06 on its consolidated financial statement disclosures.

6

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

Standard

Description

Effective Date

Effect on the Financial Statements or Other Significant Matters

In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740) -Improvements to Income Tax Disclosures."

ASU 2023-09 provides more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid.

The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. Early adoption is permitted.

The amendments in this update affects financial statement disclosure only and, as a result, will have no impact on results of operations, cash flows or financial condition.

In November 2024, the FASB issued ASU 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.”

ASU 2024-03 improves financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at both interim and annual reporting periods.

The amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027, with early adoption permitted.

ASU 2024-03 affects financial statement disclosure only and, as a result, will have no impact on results of operations, cash flows or financial condition.

In September 2025, the FASB issued ASU 2025-06, “Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40)”

ASU 2025-06 eliminates references to prescriptive software development stages and requires capitalization of internal-use software costs once management commits funding and project completion is probable, while also updating disclosure requirements to align with Property, Plant, and Equipment guidance.

The amendments in ASU 2025-06 are effective for annual periods beginning after December 15, 2027. Early adoption is permitted.

The Company is currently evaluating the impact of ASU 2025-06 on its consolidated financial statement disclosures.

2. Revenue

The Company accounts for its revenue transactions in accordance with Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers,” which requires entities to recognize revenue in a way that depicts the transfer of control over goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.
The Company recognizes revenue when control of promised goods or services is transferred to the customer. The transfer of control generally occurs upon shipment when title and risk of loss pass to the customer. The vast majority of the Company’s revenue is generated from the sale of distinct products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for such products, which is generally at contractually stated prices. Sales taxes and value added taxes collected concurrently with revenue generating activities are excluded from revenue.
Performance Obligations
Substantially all of the Company’s revenue is recognized at a point in time, upon shipment, rather than over time.
At the request of its customers, the Company may perform professional services, generally for the maintenance and repair of products previously sold to those customers and for engineering services. Professional services are typically short in duration and aggregate to less than 
3
%
 of the Company’s consolidated revenue. Revenue is typically recognized at a point in time when control transfers to the customer upon completion of professional services. These services generally involve a single distinct performance obligation. The consideration expected to be received in exchange for such services is normally the contractually stated amount.

The Company occasionally sells separately priced non-standard/extended warranty services or preventative maintenance plans with the sale of products. The transfer of control over the service plans is over time. The Company recognizes the related revenue ratably over the terms of the service plans. The transaction price of a contract is allocated to each performance obligation based on its

7

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

relative standalone selling price. Standalone selling prices are generally determined based on the prices charged to customers or using the expected cost plus a margin.
Shipping & Handling Costs
The Company accounts for shipping and handling activities that occur after the transfer of control over the related goods as fulfillment activities rather than performance obligations. Shipping and handling fees charged to customers are recognized as revenue and the related costs are recorded in cost of revenue at the time of transfer of control.
Warranties
The standard warranty periods for the Company’s products are typically 
12 months
 to 
36 months
. The Company recognizes estimated liabilities associated with standard warranty periods for its products in accordance with the provisions of ASC 450, “Contingencies,” as the Company has the ability to ascertain the likelihood of the liabilities and can reasonably estimate the amount of the liabilities.
 A provision for the estimated cost related to standard warranties is recorded as cost of revenue at the time revenue is recognized. The Company’s estimate of the costs to service the warranty obligations is based on historical experience and expectations of future conditions. To the extent that the Company’s experience in warranty claims or costs associated with servicing those claims differ from the original estimates, revisions to the estimated warranty liabilities are recorded at that time, with offsetting adjustments to cost of revenue.
Practical Expedients and Exemptions
The Company expenses incremental direct costs of obtaining a contract when incurred because the expected amortization period is typically one year or less. 
These costs are recorded within selling, general and administrative expenses in the consolidated statement of operations.
The Company does not adjust the promised amount of consideration for the effects of a financing component because the transfer of a promised good to a customer and the customer’s payment for that good are typically one year or less.

The Company does not disclose the value of the remaining performance obligation for contracts with an original expected length of one year or less.
Contract Liabilities
Contract liabilities consist of deferred revenue and advance payments from customers, including amounts that are refundable. These contract liabilities are classified as either current or long-term liabilities in the consolidated balance sheet based on the timing of when the Company expects to recognize the related revenue. As of September 26, 2025 and December 31, 2024, contract liabilities were 
$
8.2
 million
 and $
5.9
 million, respectively, and are included in accrued expenses and other current liabilities and other liabilities in the accompanying consolidated balance sheets. Th
e increase in the contract liability balance during the nine months ended September 26, 2025 is primarily due to cash payments received in advance of satisfying performance obligations, partially offset by 
$
3.0
 million 
of revenue recognized during the period that was included in the contract liability balance as of December 31, 2024.

8

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

Disaggregated Revenue
See Note 16 for the Company’s disaggregation of revenue by segment, geography and end market. 
The following table presents revenues disaggregated by the capabilities of the underlying products and technologies during the three and 
nine months ended September 26, 2025 and September 27, 2024, respectively (in thousands):

Three Months Ended

Nine Months Ended

September 26,

September 27,

September 26,

September 27,

2025

2024

2025

2024

Precision Manufacturing

$

45,180

$

48,677

$

133,596

$

152,179

Robotics and Automation

80,136

80,027

236,558

210,643

Automation Enabling Technologies

125,316

128,704

370,154

362,822

Precision Medicine

60,848

63,088

174,021

195,399

Advanced Surgery

61,672

52,613

178,076

152,964

Medical Solutions

122,520

115,701

352,097

348,363

Total Revenue

$

247,836

$

244,405

$

722,251

$

711,185

3. Business Combinations
On 
April 8, 2025
, the Company acquired 
100
% of the outstanding stock of Keonn Technologies, S.L. (“Keonn”) pursuant to the terms of a Share Purchase Agreement. 
At the closing date, Keonn became a wholly-owned subsidiary of the Company. Keonn is a manufacturer of Radio-Frequency Identification (“RFID”) solutions, based in Barcelona, Spain.
The acquisition of Keonn has been accounted for as a business combination under ASC 805, 
Business Combinations
 (“ASC 805”). Under ASC 
805,
 assets acquired and liabilities assumed in a business combination are recorded at their fair value as of the acquisition date. The Company’s consolidated financial statements include results of operations for Keonn from the April 8, 2025

acquisition date.
Consideration Transferred

Pursuant to the Share Purchase Agreement, the Company acquired all outstanding equity of Keonn for estimated total purchase consideration of $
75.1
 million, which consists of:

Cash consideration

$

68,336

Deferred consideration

2,192

Estimated fair value of contingent consideration

4,537

Estimated total purchase consideration

$

75,065

Contingent consideration represents additional payments that the Company may be required to make in the future, between €
0
 and €
20.0
 million 
(approximately $
21.9
 million as of the acquisition date), depending on the 
achievement of specified revenue targets by Keonn during fiscal years 2025 through 2027, as well as maintaining certain minimum gross margin targets during the applicable periods. The fair value of the contingent consideration was determined based on a Monte Carlo simulation model in an option pricing framework at the acquisition date, whereby a range of possible scenarios were simulated. Refer to Note 6 for additional information on the valuation assumptions utilized in the Monte Carlo simulation. Deferred consideration is related to a purchase price holdback and customary closing and net working capital adjustments which will be resolved within four years of the acquisition date.

The liabilities for contingent and deferred consideration are included in other current and long-term liabilities on the consolidated balance sheets, based on their respective settlement dates. These liabilities are remeasured at the end of each reporting period until related contingencies are resolved.

9

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

Allocation of Purchase Price

The purchase price is allocated based upon a valuation of the fair values of assets acquired and liabilities assumed. Assets acquired and liabilities assumed have been recorded at their estimated fair values as of the acquisition date. The excess of the purchase price over the fair values of the acquired tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. The fair values of identifiable intangible assets were based on valuations using an income approach, specifically the multi-period excess earnings method for customer relationships and the relief-from-royalty method for developed technologies and trade name. The process for estimating the fair values of identifiable intangible assets requires the use of significant estimates and assumptions, including revenue growth rates, customer attrition rates, royalty rates, discount rates, technology obsolescence curves, and EBITDA margins. The Company’s estimates and assumptions in determining the estimated fair value of certain assets and liabilities are subject to change within the measurement period (up to 
one year
 from the acquisition date) as a result of additional information to be obtained with regard to facts and circumstances that existed as of the acquisition date.
Based upon the Company’s preliminary valuation, the purchase price for Keonn was allocated as follows (in thousands):

Purchase

Price

Allocation

Cash

$

4,045

Accounts receivable

1,977

Inventory

5,377

Property, plant and equipment

1,401

Operating lease assets

3,124

Intangible assets

33,203

Goodwill

43,192

Other assets

1,412

Total assets acquired

93,731

Accounts payable

1,593

Operating lease liabilities

3,124

Debt

2,504

Deferred tax liabilities

7,369

Other liabilities

4,076

Total liabilities assumed

18,666

Total assets acquired, net of liabilities assumed

75,065

Less: cash acquired

4,045

Purchase price, net of cash acquired

$

71,020

The purchase price allocation is preliminary as the Company is in the process of collecting additional information. The estimated purchase price allocation previously disclosed in the Form 10-Q for the period ended June 27, 2025 was revised during the third quarter of 2025 as new information was received and analyzed resulting in an increase in identifiable intangible assets of $
0.9
 million, a decrease in goodwill of $
1.0
 million, and an increase in deferred tax liabilities of $
0.2
 million.

The fair value of intangible assets for Keonn is comprised of the following:

Estimated Fair

Amortization

Value

(In thousands)

Period

Developed technologies

$

9,753

9
 years

Customer relationships

22,354

9
 years

Trade name

1,096

14
 years

Total

$

33,203

The preliminary purchase price allocation resulted in $
33.2
 million of identifiable intangible assets and $
43.2
 million 
of goodwill. As the Keonn acquisition was structured as a stock acquisition for income tax purposes, the goodwill is not deductible. The goodwill recorded represents the anticipated incremental value of future cash flows potentially attributable to: (i) Keonn’s ability to grow the business with existing and new customers, including leveraging the Company’s customer base; (ii) Keonn’s ability to grow

10

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

the 
business through new product introductions; and (iii) cost improvements due to the integration of Keonn’s operations into the Company’s existing infrastructure.
The operating results of Keonn were included in the Company's results of operations beginning on April 8, 2025. Keonn contributed revenues of
 $
19.9
 million and profit before income taxes of $
1.0
 million to the Company's operating results for the 
nine months ended September 26, 2025. The profit before income taxes from Keonn for the period from the acquisition date through September 26, 2025
 included amortization of purchased intangible assets of $
3.7
 million.

The pro forma financial information reflecting the operating results of Keonn, as if it had been acquired as of January 1, 2024, would not differ materially from the operating results of the Company as reported for the year ended December 31, 2024.
Acquisition Costs
Acquisition costs are expensed in the periods in which the costs are incurred and included in restructuring, acquisition and related costs in the consolidated statements of operations. Acquisition-related costs for Keonn were $
2.1
 million for the 
nine months ended September 26, 2025
.
4. Accumulated Other Comprehensive Loss
Changes in accumulated other comprehensive loss were as follows (in thousands):

Total Accumulated

Other

Cumulative

Pension

Comprehensive

Translation

Liability

Loss

Adjustments

Adjustments

Balance at December 31, 2024

$

(
29,921

)

$

(
23,686

)

$

(
6,235

)

Other comprehensive income (loss)

26,519

26,960

(
441

)

Amounts reclassified from accumulated other comprehensive loss

616

—

616

Balance at September 26, 2025

$

(
2,786

)

$

3,274

$

(
6,060

)

The amounts reclassified from accumulated other comprehensive loss were included in other income (expense) in the consolidated statements of operations.
5. Earnings per Common Share

Basic earnings per common share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Fully vested restricted stock units and deferred stock units granted to members of the Company’s Board of Directors are included in the calculation of weighted average number of common shares outstanding.

For diluted earnings per common share, the denominator includes the dilutive effect of outstanding common share equivalents. The dilutive effects of outstanding common share equivalents, including outstanding service-based restricted stock units, stock options and performance-based restricted stock units, are determined using the treasury stock method. Performance-based restricted stock units are considered contingently issuable shares, the vesting of which may be based on achievement of specified company financial performance metrics (“attainment-based PSUs”), certain market conditions (“market-based PSUs”) or a hybrid of company financial performance metrics and market conditions (“hybrid PSUs”). The dilutive effects of market-based PSUs are included in the weighted average common share calculation based on the number of shares, if any, that would be issuable as of the end of the reporting period, assuming the end of the reporting period is also the end of the performance period. The dilutive effects of attainment-based and hybrid PSUs are included in the weighted average common share calculation based on the cumulative achievement against the performance targets only when the performance targets have been achieved as of the end of the reporting period.

11

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

The following table sets forth the computation of basic and diluted earnings per common share (amounts in thousands, except per share data):

Three

Months Ended

Nine Months Ended

September 26,

September 27,

September 26,

September 27,

2025

2024

2025

2024

Numerators:

Net income

$

10,653

$

19,192

$

36,358

$

47,623

Denominators:

Weighted average common shares outstanding— basic

35,967

35,959

36,004

35,940

Dilutive common share equivalents

73

170

78

176

Weighted average common shares outstanding— diluted

36,040

36,129

36,082

36,116

Antidilutive common share equivalents excluded from above

295

102

271

113

Earnings per Common Share:

Basic

$

0.30

$

0.53

$

1.01

$

1.33

Diluted

$

0.30

$

0.53

$

1.01

$

1.32

For the three and nine months ended September 26, 2025, 
285
 thousand shares of attainment-based PSUs and hybrid PSUs were excluded from the calculation of the denominator because they were considered contingently issuable shares and the related performance targets had not been achieved as of September 26, 2025.
For the three and nine months ended September 27, 2024
, 
174
 thousand shares of attainment-based PSUs and hybrid PSUs were excluded from the calculation of the denominator because they were considered contingently issuable shares and the related performance targets had not been achieved as of 
September 27, 2024
.
6. Fair Value Measurements

ASC 820, “Fair Value Measurements,” establishes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the third is considered unobservable:

•
Level 1: Quoted prices for identical assets or liabilities in active markets which the Company can access
•
Level 2: Observable inputs other than those described in Level 1
•
Level 3: Unobservable inputs
Current Assets and Liabilities
The Company’s cash equivalents are highly liquid investments with original maturities of three months or less, which represent assets measured at fair value on a recurring basis. The Company determines the fair value of cash equivalents using a market approach based on quoted prices in active markets. The fair values of cash equivalents, accounts receivable, income taxes receivable, accounts payable, income taxes payable and accrued expenses and other current liabilities approximate their carrying values because of their short-term nature.

Foreign Currency Contracts
The Company addresses market risks from changes in foreign currency exchange rates through a risk management program that includes the use of derivative financial instruments to mitigate certain balance sheet foreign currency transaction exposures. The Company uses foreign currency forward contracts as a part of its strategy to manage exposures related to foreign currency denominated monetary assets and liabilities. The fair value of these foreign currency forward contracts is reported either in other current assets or in other current liabilities as of the end of the reporting period.

12

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

Contingent Considerations
On April 8, 2025, the Company completed the acquisition of Keonn. Pursuant to the purchase and sale agreement, the former shareholders of Keonn (the “Sellers”) are eligible to receive contingent consideration based on the achievement of specified revenue targets by Keonn during fiscal years 2025 through 2027. Payment of this contingent consideration is also subject to Keonn maintaining certain minimum gross margin percentage during the applicable periods. The undiscounted range of potential contingent consideration is between €
0
 and €
20.0
 million 
(approximately $
21.9
 million). I
f the performance conditions are met, the contingent consideration will be payable annually, with the first payment due in the second quarter of 2026. As of the acquisition date, the estimated fair value of the contingent consideration wa
s €
4.1
 million (approximately $
4.5
 million), determin
ed using the Monte Carlo valuation method. This amount was recorded as part of the purchase price. Subsequent changes in the estimated fair value are recognized in the consolidated statement of operations in restructuring, acquisition, and related costs until the liability is fully settled. There have been 
no
 changes in the fair value of the contingent consideration since the acquisition date.

Summary by Fair Value Hierarchy
The following table summarizes the fair values of the Company’s assets and liabilities measured at fair value on a recurring basis as of 
September 26, 2025 (in thousands):

Quoted Prices in

Significant Other

Active Markets for

Significant Other

Unobservable

Identical Assets

Observable Inputs

Inputs

Fair Value

(Level 1)

(Level 2)

(Level 3)

Assets

Prepaid expenses and other current assets:

Foreign currency forward contracts

$

194

$

—

$

194

$

—

$

194

$

—

$

194

$

—

Liabilities

Accrued expenses and other current liabilities:

Contingent considerations - Current

$

4,469

$

—

$

—

$

4,469

Contingent considerations - Long term

459

—

—

459

Foreign currency forward contracts

222

—

222

—

$

5,150

$

—

$

222

$

4,928

The following table summarizes the fair values of the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2024 (in thousands):

Quoted Prices in

Significant Other

Active Markets for

Significant Other

Unobservable

Identical Assets

Observable Inputs

Inputs

Fair Value

(Level 1)

(Level 2)

(Level 3)

Assets

Prepaid expenses and other current assets:

Foreign currency forward contracts

$

1,226

$

—

$

1,226

$

—

$

1,226

$

—

$

1,226

$

—

Liabilities

Accrued expenses and other current liabilities:

Contingent considerations - Current

$

57

$

—

$

—

$

57

Foreign currency forward contracts

1,401

—

1,401

—

$

1,458

$

—

$

1,401

$

57

13

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

Changes in the fair value of Level 3 contingent considerations during the 
nine months ended September 26, 2025 were as follows (in thousands):

Amount

Balance at December 31, 2024

$

57

Acquisition of Keonn

4,537

Payments

—

Fair value adjustments

—

Effect of foreign exchange rates

334

Balance at September 26, 2025

$

4,928

The following table provides qualitative information associated with the fair value measurement of the Company’s Level 3 liabilities:

Liability

September 26, 2025 Fair Value
(in thousands)

Valuation Technique

Unobservable Inputs

Percentage Applied

Contingent consideration (Keonn)

$
4,864

Monte Carlo method

Historical and projected revenue from fiscal year 2025 to 2027

N/A

Gross Profit Premium

8.8
%

Revenue risk premium

8.0
%

Gross Profit Volatility

44.0
%

Revenue Volatility

40.0
%

Credit spread

3.6
%

See Note 10 to Consolidated Financial Statements for a discussion of the estimated fair value of the Company’s outstanding debt.
7. Foreign Currency Contracts

The Company addresses market risks from changes in foreign currency exchange rates through a risk management program that includes the use of derivative financial instruments to mitigate certain foreign currency transaction exposures from future settlement of non-functional currency monetary assets and liabilities as of the end of a period. The Company does not enter into derivative transactions for speculative purposes. Gains and losses on these derivative financial instruments substantially offset losses and gains on the underlying hedged exposures and are included in foreign exchange transaction gains (losses) in the consolidated statements of operations. Furthermore, the Company manages its exposures to counterparty risks on derivative instruments by entering into contracts with a diversified group of major financial institutions and by actively monitoring outstanding positions.
As of September 26, 2025, the aggregate notional amount and fair value of the Company’s foreign currency forward contracts was 
$
50.2
 million and a net loss of less than $
0.1
 million
, respectively. As of December 31, 2024, the aggregate notional amount and fair value of the Company’s foreign currency forward contracts was $
187.4
 million and a net loss of $
0.2
 million, respectively.
The Company recognized an aggregate ne
t loss of $
0.4
 million and $
2.2
 million f
or the three and nine months ended September 26, 2025
 and an aggregate net gain of $
2.1
 million and $
4.3
 million for the three and 
nine months ended September 27, 2024
. These amounts were included in foreign exchange transaction gains (losses) in the consolidated statements of operations.
8. Goodwill and Intangible Assets

Goodwill

Goodwill is recorded when the consideration paid for a business combination exceeds the fair value of net tangible and identifiable intangible assets acquired. The Company tests its goodwill balances for impairment annually as of the beginning of the second quarter or more frequently if indicators are present or changes in circumstances suggest that an impairment may exist. The Company performed the most recent annual goodwill and indefinite-lived intangible asset impairment test as of the beginning of the second quarter of 
2025 and noted 
no
 impairment.

14

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

The following table summarizes changes in goodwill during the 
nine months ended September 26, 2025 (in thousands):

Amount

Balance at beginning of the period

$

584,098

Goodwill acquired from Keonn acquisition

43,192

Effect of foreign exchange rate changes

20,223

Balance at end of the period

$

647,513

Goodwill by reportable segment as of 
September 26, 2025 was as follows (in thousands):

Reportable Segment

Automation Enabling Technologies

Medical Solutions

Total

Goodwill

$

447,383

$

351,359

$

798,742

Accumulated impairment of goodwill

(
119,507

)

(
31,722

)

(
151,229

)

Total

$

327,876

$

319,637

$

647,513

Goodwill by reportable segment as of December 31, 2024 was as follows (in thousands): 

Reportable Segment

Automation Enabling Technologies

Medical Solutions

Total

Goodwill

$

439,980

$

295,347

$

735,327

Accumulated impairment of goodwill

(
119,507

)

(
31,722

)

(
151,229

)

Total

$

320,473

$

263,625

$

584,098

Intangible Assets

Intangible assets as of 
September 26, 2025 and December 31, 2024, respectively, are summarized as follows (in thousands):

September 26, 2025

December 31, 2024

Gross Carrying
Amount

Accumulated
Amortization

Net Carrying
Amount

Gross

Carrying
Amount

Accumulated
Amortization

Net Carrying
Amount

Amortizable intangible assets:

Patents and developed technologies

$

235,926

$

(
176,601

)

$

59,325

$

218,867

$

(
159,041

)

$

59,826

Customer relationships

297,007

(
183,314

)

113,693

265,156

(
158,938

)

106,218

Trademarks and trade names

25,270

(
18,067

)

7,203

23,367

(
16,594

)

6,773

Amortizable intangible assets

558,203

(
377,982

)

180,221

507,390

(
334,573

)

172,817

Non-amortizable intangible assets:

Trade names

13,027

—

13,027

13,027

—

13,027

Total intangible assets

$

571,230

$

(
377,982

)

$

193,248

$

520,417

$

(
334,573

)

$

185,844

All definite-lived intangible assets are amortized either on a straight-line basis or an economic benefit basis over their remaining estimated useful life. Amortization expense for patents and developed technologies is included in cost of revenue in the accompanying consolidated statements of operations. Amortization expense for customer relationships and definite-lived trademarks, trade names and other intangibles is included in operating expenses in the accompanying consolidated statements of operations. 
Amortization expense was as follows (in thousands): 

Three

Months Ended

Nine Months Ended

September 26,

September 27,

September 26,

September 27,

2025

2024

2025

2024

Amortization expense – cost of revenue

$

4,252

$

3,708

$

12,031

$

11,086

Amortization expense – operating expenses

6,928

6,589

19,353

19,246

Total amortization expense

$

11,180

$

10,297

$

31,384

$

30,332

15

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

As of 
September 26, 2025, estimated amortization expense for each of the five succeeding years and thereafter was as follows (in thousands):

Year Ending December 31,

Cost of Revenue

Operating
Expenses

Total

2025 (remainder of year)

$

4,255

$

7,085

$

11,340

2026

15,048

23,079

38,127

2027

12,121

19,226

31,347

2028

10,313

16,180

26,493

2029

7,442

12,567

20,009

Thereafter

10,146

42,759

52,905

Total

$

59,325

$

120,896

$

180,221

9. Supplementary Balance Sheet Information

The following tables provide the details of selected balance sheet items as of the periods indicated (in thousands):

Inventories

September 26,

December 31,

2025

2024

Raw materials

$

114,921

$

92,198

Work-in-process

31,025

24,719

Finished goods

33,533

27,327

Demo and consigned inventory

498

362

Total inventories

$

179,977

$

144,606

Accrued Expenses and Other Current Liabilities

September 26,

December 31,

2025

2024

Accrued compensation and benefits

$

17,035

$

28,361

Accrued warranty

5,552

4,805

Contract liabilities, current portion

8,030

5,715

Accrued restructuring

12,924

6,131

Accrued earn-outs and contingent considerations

4,469

57

Other

18,783

15,262

Total

$

66,793

$

60,331

Accrued Warranty

Nine Months Ended

September 26,

September 27,

2025

2024

Balance at beginning of the period

$

4,805

$

5,292

Provision charged to cost of revenue

2,685

888

Warranty liabilities acquired from acquisitions

—

76

Use of provision

(
2,022

)

(
1,322

)

Foreign currency exchange rate changes

84

48

Balance at end of the period

$

5,552

$

4,982

16

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

Other Long-Term Liabilities

September 26,

December 31,

2025

2024

Finance lease obligations

$

2,565

$

3,175

Other

3,921

1,316

Total

$

6,486

$

4,491

10. Debt

Outstanding debt consisted of the following (in thousands):

September 26,

December 31,

2025

2024

Senior Credit Facilities – term loans

$

5,779

$

4,710

Less: unamortized debt issuance costs

(
94

)

(
19

)

Total current portion of long-term debt

$

5,685

$

4,691

Senior Credit Facilities – term loans

$

144,612

$

65,698

Senior Credit Facilities – revolving credit facility

306,613

348,751

Less: unamortized debt issuance costs

(
5,567

)

(
2,500

)

Total long-term debt

$

445,658

$

411,949

Total Senior Credit Facilities

$

451,343

$

416,640

Senior Credit Facilities

On June 27, 2025, the Company entered into an amended and restated credit agreement (the “Fourth Amended and Restated Credit Agreement”) with existing and new lenders for an aggregate credit facility of approximately $
1.0
 billion, consisting of a €
65.3
 million euro-denominated 
5
-year term loan facility (the “Euro Term Loans”), a $
75.0
 million U.S. Dollar denominated 
5
-year term loan facility (the “U.S. Term Loans” and together with the Euro Term Loans, the “Term Loans”), and an $
850.0
 million 
5
-year revolving credit facility (the “Revolving Facility”, and together with the Euro Term Loans and the U.S. Term Loans, collectively, the “Senior Credit Facilities”). The Senior Credit Facilities mature in 
June 2030
 and include an uncommitted “accordion” feature pursuant to which the commitments thereunder may be increased by an additional $
350.0
 million in aggregate, subject to the satisfacti
on of certain customary conditions. In connection with the Fourth Amended and Restated Credit Agreement, the Company capitalized $
4.3
 million deferred financing costs and recorded a $
0.4
 million loss fro
m the write-off of a portion of the unamortized deferred financing costs.

The outstanding principal balance under the Euro Term Loans is payable in 
quarterly
 installments 
of €
1.1
 million (approximately $
1.3
 million), beginning in September 2025, with the remaining balance due upon maturity. The U.S. Term Loans require 
quarterly
 installment payments of $
0.5
 million starting in September 2026, increasing to $
0.9
 million beginning in September 2027, with the remaining balance also due upon maturity. The Company may make additional principal payments at any time, which will reduce the next scheduled installment. Borrowings under the Revolving Facility may be repaid at any time prior to maturity. The Company made principal payments of €
3.4
 million ($
3.8
 million) towards the Term Loans and $
45.4
 million towards its Revolving Facility during the 
nine months ended September 26, 2025.
The Company is required to satisfy certain financial and non-financial covenants under the Fourth Amended and Restated Credit Agreement. The Fourth Amended and Restated Credit Agreement also contains customary events of default. The Company was in compliance with these covenants as of September 26, 2025.

Liens
The Company’s obligations under the Senior Credit Facilities are secured, on a senior basis, by a lien on substantially all of the assets of Novanta Inc.

17

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

Fair Value of Debt

As of September 26, 2025
 and December 31, 2024, the outstanding balance of the Company’s debt approximated its fair value based on current rates available to the Company for debt of similar maturities. The fair value of the Company’s debt is classified as Level 2 under the fair value hierarchy.
11. Leases
Most leases held by the Company expire between 
2025
 and 
2037
. In the U.K., where longer lease terms are more common, the Company has a land lease that extends through 
2078
. 
Certain leases include one or more options to renew the lease terms from 
one
 to 
ten years
 and options to terminate the leases within 
one year
.
 The exercise of lease renewal or termination options is at the Company’s sole discretion; therefore, the majority of renewal options to extend the lease terms are not included in the Company’s right-of-use assets and operating lease liabilities as they are not reasonably certain of being exercised. The Company regularly evaluates the renewal options and includes the renewal periods in the lease term when they are reasonably certain of being exercised. The depreciable lives of the right-of-use assets and leasehold improvements are limited to the expected lease terms.
The following table summarizes the components of lease costs (in thousands):

Three

Months Ended

Nine Months Ended

September 26,

September 27,

September 26,

September 27,

2025

2024

2025

2024

Operating lease cost

$

2,745

$

3,466

$

8,365

$

9,267

Finance lease cost

Amortization of right-of-use assets

150

151

451

452

Interest on lease liabilities

48

58

150

180

Variable lease cost

284

303

954

895

Total lease cost

$

3,227

$

3,978

$

9,920

$

10,794

18

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

The following table provides additional details of balance sheet information related to the Company’s leases (in thousands, except lease term and discount rate):

September 26,

December 31,

2025

2024

Operating leases

Operating lease right-of-use assets

$

43,283

$

42,908

Current portion of operating lease liabilities

$

10,165

$

9,879

Operating lease liabilities

40,407

40,548

Total operating lease liabilities

$

50,572

$

50,427

Finance leases

Property, plant and equipment, gross

$

9,582

$

9,582

Accumulated depreciation

(
7,325

)

(
6,874

)

Finance lease assets included in property, plant and equipment, net

$

2,257

$

2,708

Accrued expenses and other current liabilities

$

804

$

759

Other liabilities

2,565

3,175

Total finance lease liabilities

$

3,369

$

3,934

Weighted-average remaining lease term (in years):

Operating leases

7.4

7.4

Finance leases

3.8

4.5

Weighted-average discount rate:

Operating leases

4.85

%

4.82

%

Finance leases

5.54

%

5.54

%

The following table provides additional details of cash flow information related to the Company’s leases (in thousands):

Nine Months Ended

September 26,

September 27,

2025

2024

Cash paid for lease liabilities:

Operating cash outflows related to finance leases

$

150

$

180

Operating cash outflows related to operating leases

$

7,566

$

6,723

Financing cash outflows related to finance leases

$

565

$

534

Supplemental non-cash information:

Right-of-use assets obtained in exchange for new operating lease liabilities
(1)

$

5,512

$

12,733

(1)
 The amount for the nine months ended September 26, 2025
 includes $
3.1
 million of right-of-use assets acquired as part of the Keonn acquisition. The amount for the 
nine months ended September 27, 2024
 includes $
8.1
 million of right-of-use assets acquired as part of the Motion Solutions Parent Corp. acquisition.

19

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

Future minimum lease payments under operating and finance leases expiring subsequent to 
September 26, 2025, including operating leases associated with facilities that have been vacated as a result of the Company’s restructuring actions, are summarized as follows (in thousands):

Year Ending December 31,

Operating Leases

Finance Leases

2025 (remainder of year)

$

3,117

$

238

2026

11,701

979

2027

10,207

1,003

2028

7,278

1,003

2029

6,316

502

Thereafter

23,000

—

Total minimum lease payments

61,619

3,725

Less: Interest

(
11,047

)

(
356

)

Present value of lease liabilities

$

50,572

$

3,369

12. Preferred and Common Shares and Share-Based Compensation
Preferred Shares
In May 2021, the Company’s shareholders approved a special resolution to amend the Company’s articles to authorize up to 
7.0
 million preferred shares for future issuance. The Company’s Board of Directors is authorized to designate and issue one or more series of preferred shares, fix the rights, preferences and designation, as deemed necessary or advisable, relating to the preferred shares, provided that no shares of any series may be entitled to more than 
one vote per share
. As of 
September 26, 2025
, 
no
 preferred shares had been issued and outstanding.
Common Share Repurchases
In February 2020, the Company’s Board of Directors approved a share repurchase plan (the “2020 Repurchase Plan”), 
authorizing the repurchase of $
50.0
 million worth of the Company’s common shares. During the 
nine months ended September 26, 2025
, the Company repurchased 
179
 thousand shares under the 2020 Repurchase Plan for an aggregate purchase price of $
21.1
 million and an average price of $
118.09
 per share. As of 
September 26, 2025, the Company had
 $
28.4

million available for future share repurchases under the 2020 Repurchase Plan.

In September 2025, the Company’s Board of Directors approved a new share repurchase plan (the “2025 Repurchase Plan”) authorizing the repurchase of an additional $
200.0
 million worth of common shares. The Company expects that share repurchases will be made under the 2025 Repurchase Plan after the 2020 Repurchase Plan is completed. As of 
September 26, 2025
, 
no
 shares had been repurchase under the 2025 Repurchase Plan.

Share-Based Compensation Expense
The table below summarizes share-based compensation expense recorded in the consolidated statements of operations (in thousands):

Three

Months Ended

Nine Months Ended

September 26,

September 27,

September 26,

September 27,

2025

2024

2025

2024

Selling, general and administrative

$

4,663

$

5,357

$

17,189

$

16,006

Research and development and engineering

1,123

636

2,387

1,796

Cost of revenue

912

371

1,720

870

Total share-based compensation expense

$

6,698

$

6,364

$

21,296

$

18,672

Share-based compensation expense reported in selling, general and administrative expenses included expenses related to restricted stock units granted to the members of the Company’s Board of Directors of
 $
1.6
 million 
and $
1.6
 million during the 
nine months ended September 26, 2025 and September 27, 2024, respectively.

20

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

Restricted Stock Units
The Company’s restricted stock units (“RSUs”) have generally been issued with vesting periods ranging from 
zero
 to 
four years
 and vest based solely on service conditions. Accordingly, the Company recognizes compensation expense on a straight-line basis over the requisite service period. The Company reduces the compensation expense by an estimated forfeiture rate which is based on anticipated forfeitures and historical forfeiture experience.
The table below summarizes activities relating to RSUs issued and outstanding under the Company’s Amended and Restated 2010 Incentive Plan during the 
nine months ended September 26, 2025:

Shares
(In thousands)

Weighted
Average Grant
Date Fair Value

Unvested at December 31, 2024

198

$

154.43

Granted

320

$

129.95

Vested

(
91

)

$

147.12

Forfeited

(
44

)

$

142.78

Unvested at September 26, 2025

383

$

137.06

Expected to vest as of September 26, 2025

351

The total fair value of RSUs that vested during the nine months ended September 26, 2025 was $
12.3
 million
 based on the market price of the underlying shares on the date of vesting.

Performance Stock Units
The Company typically grants PSUs that are based on the Company’s financial performance metrics, market conditions, or a hybrid of company financial performance metrics and market conditions. These PSUs generally cliff vest on the first day following the end of the specified performance period.
The number of common shares to be issued upon settlement following vesting of attainment-based PSUs is determined based on the Company’s financial performance metrics over the specified performance period against the targets established by the Company’s Board of Directors at the time of grant and will be in the range of 
zero
 to 
200
% of the target number of shares. The Company recognizes the related compensation expense ratably over the performance period based on the number of shares that are deemed probable of vesting at the end of the specified performance period. This probability assessment is performed quarterly and the cumulative effect of a change in the estimated compensation expense, if any, is recognized in the consolidated statement of operations in the period in which such determination is made.

The number of common shares to be issued upon settlement following vesting of market-based PSUs is determined based on the relative market performance of the Company’s common shares compared to the Russell 2000 Index over the specified performance period using a payout formula established by the Company’s Board of Directors at the time of grant and will be in the range of 
zero
 to 
200
% of the target number of shares. The Company recognizes the related compensation expense based on the fair value of the market-based PSUs, determined using the Monte-Carlo valuation method as of the grant date, on a straight-line basis from the grant date to the end of the specified performance period. Compensation expense on market-based PSUs will not be affected by the number of shares that will ultimately vest at the end of the specified performance period.
The number of common shares to be issued upon settlement following vesting of PSU awards that are based on the achievement of a hybrid of company financial performance metrics and market conditions (“Hybrid PSUs”) is determined based on the Company's financial performance metrics achieved over the specified performance period against the targets established by the Company's Board of Directors at the time of grant and a market-based multiplier based on the percentile ranking of the relative market performance of the Company’s common shares compared to the Russell 2000 Index companies. The payout will be in the range of 
zero
 to 
260
% 
of the target number of shares. The Company determines the fair value of these Hybrid PSUs using the Monte-Carlo valuation method as of the grant date. The Company recognizes compensation expense associated with the Hybrid PSUs ratably over the performance period based on the fair value of the PSUs as of the grant date and the number of shares that are deemed probable of vesting based on the estimated achievement of the pertinent company financial performance metrics at the end of the specified performance period. The probability assessment is performed quarterly and the cumulative effect of a change in the

21

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

estimated 
compensation expense, if any, is recognized in the consolidated statement of operations in the period in which such determination is made.
The table below summarizes the activities relating to the performance-based awards issued and outstanding under the Company’s Amended and Restated 2010 Incentive Plan during the 
nine months ended September 26, 2025:

Shares
(In thousands)

Weighted
Average Grant-
Date Fair Value

Unvested at December 31, 2024

227

$

165.13

Granted

157

$

133.11

Performance adjustments
(1)

(
8

)

$

143.51

Vested

(
53

)

$

141.33

Forfeited

(
20

)

$

167.60

Unvested at September 26, 2025

303

$

153.14

Expected to vest as of September 26, 2025

230

(1) 
The amount shown represents performance adjustments related to the performance-based awards vested during the nine months ended September 26, 2025
.
The unvested PSUs are shown at target payout levels in the table above. As of September 26, 2025
, the maximum number of common shares that could be earned under these PSU grants was approximately 
594
 thousand shares.
The total fair value of PSUs that vested during the nine months ended September 26, 2025 was
 $
7.6
 million b
ased on the market price of the underlying common shares on the date of vesting.
The grant-date fair value per unit of the hybrid PSUs granted during the 
nine months ended September 26, 2025 was estimated using the Monte Carlo valuation method with the following assumptions:

Nine Months Ended September 26, 2025

Grant-date stock price

$

142.80

Expected volatility

36.94

%

Risk-free interest rate

4.18

%

Expected annual dividend yield

—

Fair value

$

160.93

Stock Options
The table below summarizes the activities relating to stock options issued and outstanding under the Company’s Amended and Restated 2010 Incentive Plan during the 
nine months ended September 26, 2025:

Shares
(In thousands)

Weighted
Average Exercise Price

Outstanding as of December 31, 2024

149

$

139.17

Granted

—

$

—

Exercised

(
4

)

$

135.86

Forfeited or expired

(
5

)

$

157.04

Outstanding as of September 26, 2025

140

$

138.56

Exercisable as of September 26, 2025

96

Expected to vest as of September 26, 2025

44

22

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

13. Income Taxes

The Company determines its estimated annual effective tax rate at the end of each interim period based on full year forecasted pre-tax income and facts known at that time. The estimated annual effective tax rate is applied to the year-to-date pre-tax income at the end of each interim period with the cumulative effect of any changes in the estimated annual effective tax rate being recorded in the period in which the changes are determined. The tax effect of significant unusual items is reflected in the period in which they occur. Since the Company is incorporated in Canada, it is required to use Canada’s statutory tax rate of 
29.0
% in the determination of the estimated annual effective tax rate.
The Company maintains a valuation allowance on balances of certain U.S. state net operating losses, credits and certain non-U.S. tax attributes that the Company has determined are not more likely than not to be realized. A valuation allowance is required when, based upon an assessment of various factors, including recent operating loss history, anticipated future earnings, and prudent and reasonable tax planning strategies, it is more likely than not that some portion of the deferred tax assets will not be realized. In conjunction with the Company’s ongoing review of its actual results and anticipated future earnings, the Company continuously reassesses the possibility of adding a new or additional valuation allowance or releasing the valuation allowance currently in place on its deferred tax assets.

The Company’s effective tax rate of 
32.4
% for the three months ended September 26, 2025 differs from the Canadian statutory tax rate of 
29.0
% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated U.S. tax benefits for Foreign Derived Intangible Income (“FDII”) and R&D tax credits, and U.K. patent box deductions; partially offset by various non-deductible transaction-related and compensation expenses and uncertain tax position accruals.
The Company’s effective tax rate of 
24.2
% for the nine months ended September 26, 2025 differs from the Canadian statutory tax rate of 
29.0
% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated U.S. tax benefits for FDII and R&D tax credits, and U.K. patent box deductions; partially offset by various non-deductible transaction-related and compensation expenses and uncertain tax position accruals.
The Company’s effective tax rate of 
20.8
% for the three months ended September 27, 2024 differs from the Canadian statutory tax rate of 
29.0
% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated deductions for FDII, U.K. patent box deductions and R&D tax credits, partially offset by disallowed compensation deductions, uncertain tax position accruals, and Pillar Two inclusion.
The Company’s effective tax rate of 
18.3
% for the nine months ended September 27, 2024 differs from the Canadian statutory tax rate of 
29.0
% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated deductions for FDII, U.K. patent box deductions, R&D tax credits, and windfall tax benefits upon vesting of certain share-based compensation awards, partially offset by disallowed compensation deductions, uncertain tax position accruals, and Pillar Two inclusion. For the nine months ended September 27, 2024, the tax benefits upon vesting of certain share-based compensation awards had a benefit of 
3.1
% on the Company’s effective tax rate.

On July 4, 2025, the U.S. enacted H.R.1 - One Big Beautiful Bill Act (the “Act”). The Act contains numerous income tax provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act and modifications to the international tax framework. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. The Company continues to evaluate the implications of the Act on its consolidated financial statements and related disclosures. The Company has included an estimated impact of items affecting its income tax expense for the three and nine months ended September 26, 2025
.

23

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

14. Restructuring, Acquisition, and Related Costs

The following table summarizes restructuring, acquisition, and related costs in the accompanying consolidated statements of operations (in thousands):

Three

Months Ended

Nine Months Ended

September 26,

September 27,

September 26,

September 27,

2025

2024

2025

2024

2025 restructuring

$

4,261

$

—

$

11,097

$

—

2024 restructuring

942

1,919

4,917

4,990

2020 restructuring

—

—

(
3,595

)

—

Total restructuring charges

5,203

1,919

12,419

4,990

Acquisition and related charges

1,474

580

4,375

2,335

Total restructuring, acquisition, and related costs

$

6,677

$

2,499

$

16,794

$

7,325

2025 Restructuring
The Company initiated the 2025 restructuring program in the second quarter of 2025 in order to streamline operations and align with our long-term goals. The 2025 restructuring program includes measures to regionalize manufacturing operations, expedite the closure of certain sites, streamline management structures, and implement cost-saving strategies in areas anticipated to have a minimal long-term impact on the Company's overall business performance. During both the three and 
nine months ended September 26, 2025, the Company r
ecorded $
4.3
 million and $
11.1
 million, respectively, in severance, facility related and other charges in connection with the 2025 restructuring program. As of 
September 26, 2025
, the Company had incurred cumulative costs of $
11.1
 million 
related to this restructuring program. The Company anticipates substantially completing the 2025 restructuring program by th
e end of 2026. Total restructuring charges related to this program are expected to be approximately $
20.0
 million.
The following 
table summarizes restructuring costs associated with the 2025 restructuring program by reportable segment (in thousands):

Three

Months Ended

Nine Months Ended

September 26,

September 27,

September 26,

September 27,

2025

2024

2025

2024

Automation Enabling Technologies

$

694

$

—

$

1,634

$

—

Medical Solutions

2,490

—

6,692

—

Unallocated

1,077

—

2,771

—

Total

$

4,261

$

—

$

11,097

$

—

2024 Restructuring
As a result of the Company’s acquisitions and ongoing integration activities, the Company initiated the 2024 restructuring program in the first quarter of 2024 in order to reduce operating complexity. During the three and 
nine months ended September 26, 2025, the Comp
any recorded $
0.9
 million and $
4.9
 million, respectively, in severance, facility related and other charges in connection with the 2024 restructuring program. As of 
September 26, 2025
, the Company had incurred cumulative costs of $
15.4
 million related to this restructuring program. The Company anticipates substantially completing the 2024 restructuring program by the end of 2026 and expects to incur additional restructuring charges of $
1.5
 million to $
2.5
 million related to the 
2024 restructuring program.

24

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

The following 
table summarizes restructuring costs associated with the 2024 restructuring program by reportable segment (in thousands):

Three

Months Ended

Nine Months Ended

September 26,

September 27,

September 26,

September 27,

2025

2024

2025

2024

Automation Enabling Technologies

$

397

$

809

$

1,328

$

2,898

Medical Solutions

545

1,037

3,557

1,603

Unallocated

—

73

32

489

Total

$

942

$

1,919

$

4,917

$

4,990

2020 Restructuring
As a result of the Company’s ongoing evaluations and efforts to reduce its operating costs, while improving efficiency and effectiveness, the Company initiated the 2020 restructuring program in the third quarter of 2020. This program was focused on reducing operating complexity in the Company, including reducing infrastructure costs and streamlining the Company’s operating model to better serve its customers. In addition, the program was focused on cost reduction actions to improve gross margins for the overall company. As of 
September 26, 2025, the Company had incurred cumulative costs o
f $
13.1
 million
 related to the 2020 restructuring program. The 2020 restructuring program activities were completed in the fourth quarter of 2023. In January 2025, the Company sold a facility from the 2020 restructuring program and recorded a $
3.6
 million gain in the Company’s Automation Enabling Technologies segment.
Roll-forward of Accrued Expenses Related to Restructuring

The following table summarizes the accrual activities, by component, related to the Company’s restructuring plans recorded in the accompanying consolidated balance sheets (in thousands):

Total

Employee Related

Facility

Related

Facility Sale

Other

Balance at December 31, 2024

$

6,751

$

5,690

$

1,061

$

—

$

—

Restructuring charges

12,419

12,787

2,197

(
4,077

)

1,512

Cash payments

(
2,987

)

(
6,923

)

(
345

)

5,537

(
1,256

)

Non-cash write-offs and other adjustments

(
2,849

)

724

(
2,113

)

(
1,460

)

—

Balance at September 26, 2025

$

13,334

$

12,278

$

800

$

—

$

256

Acquisition and Related Charges

Acquisition cost
s in connection with business combinations, including advisor, legal, valuation, and other professional or consulting fees, totaled $
1.5
 million and $
4.4
 million f
or the three and nine months ended September 26, 2025
, and $
0.6
 million and $
2.3
 million for the three and 
nine months ended September 27, 2024. The majority of acquisition and related costs for the three and nine months ended September 26, 2025 and the three and nine months ended September 27, 2024
 were included in unallocated costs.
15. Commitments and Contingencies

Purchase Commitments

There have been no material changes to the Company’s purchase commitments since December 31, 2024.
Legal Contingencies

The Company is subject to various legal proceedings and claims that arise in the ordinary course of business. The Company reviews the status of each significant matter and assesses the potential financial exposure on a quarterly basis. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best

25

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

information available as of the date of the consolidated balance sheet. As additional information becomes available, the Company reassesses the potential liability related to any pending claims and litigation and may revise its estimates. When a material loss contingency is considered reasonably possible but not probable, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the potential loss or a range of potential losses, if such an estimate can be reasonably made. Legal fees are expensed as incurred. The Company does not believe that the outcome of outstanding claims will have a material adverse effect on its consolidated financial statements but there can be no assurance that any such claims, or any similar claims, would not have a material adverse effect on its consolidated financial statements.

Guarantees and Indemnifications

In the normal course of its operations, the Company executes agreements that provide for indemnification and guarantees to counterparties in transactions such as business dispositions, sale of assets, sale of products, and operating leases. Additionally, the by-laws of the Company require it to indemnify certain current or former directors, officers, and employees of the Company against expenses incurred by them in connection with each proceeding in which they are involved as a result of serving or having served in certain capacities. Indemnification is not available with respect to a proceeding as to which it has been adjudicated that the person did not act in good faith in the reasonable belief that the action was in the best interests of the Company. Certain of the Company’s officers and directors are also a party to indemnification agreements with the Company. These indemnification agreements provide, among other things, that the director or officer shall be indemnified to the fullest extent permitted by applicable law against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such director or officer in connection with any proceeding by reason of their relationship with the Company. In addition, the indemnification agreements provide for the advancement of expenses incurred by such director or officer in connection with any proceeding covered by the indemnification agreement, subject to the conditions set forth therein and to the extent such advancement is not prohibited by law. The indemnification agreements also set out the procedures for determining entitlement to indemnification, the requirements relating to notice and defense of claims for which indemnification is sought, the procedures for enforcement of indemnification rights, the limitations on and exclusions from indemnification, and the minimum levels of directors and officers liability insurance to be maintained by the Company.

16. Segment Information

Reportable Segments

The Company’s Chief Operating Decision Maker (“CODM”) is the 
Chief Executive Officer
. 
The CODM utilizes financial information to make decisions about allocating resources and assessing performance for the entire Company.
 The CODM evaluates the performance of, and allocates resources to, its segments based on revenue, gross profit and operating income. The Company’s reportable segments have been identified based on commonality and adjacency of end markets and customers amongst the Company’s individual product lines.

During the fourth quarter of 2024, the Company updated its organizational structure and re-aligned its financial reporting structure under 
two
 reportable segments: Automation Enabling Technologies and Medical Solutions. Prior to the reorganization, the Company
's historical reportable segments were: Precision Medicine and Manufacturing, Robotics and Automation, and Medical Solutions. Prior period segment financial information has been recast to align with the new reportable segments herein, as well as in Notes 8 and 14.
Automation Enabling Technologies
The Automation Enabling Technologies segment designs, manufactures and markets laser beam delivery components, laser beam delivery solutions, CO
2
 lasers, solid state lasers, ultrafast lasers, optical and inductive encoders, precision motors, integrated stepper motors, servo drives, motion control solutions, intelligent robotic end-of-arm technology solutions, and air bearing spindles to customers worldwide. The segment serves highly demanding applications for advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures such as ophthalmology applications. The vast majority of the segment’s product offerings are sold to OEM customers. The segment sells the majority of these products directly, utilizing a highly technical sales force, and also sells some indirectly, through resellers and distributors.

26

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

Medical Solutions

The Medical Solutions segment designs, manufactures and markets a range of medical grade technologies, including medical insufflators and endoscopic pumps and related disposables, laser beam delivery solutions, video processing and streaming and capture, machine vision technologies, radio-frequency identification (“RFID”) technologies, barcode identification technologies, thermal chart recorders, light and color measurement technologies, touch panel displays, and advanced motion control solutions. The vast majority of the segment’s product offerings are sold to OEM customers. The segment sells the majority of these products directly, utilizing a highly technical sales force, and also sells some indirectly, through resellers and distributors.
Reportable Segment Financial Information

Results of operations, depreciation and amortization expenses by reportable segments for the periods indicated were as follows (in thousands):

Three Months Ended September 26, 2025

Nine Months Ended September 26, 2025

Automation Enabling Technologies

Medical Solutions

Total

Automation Enabling Technologies

Medical Solutions

Total

Revenue

$

125,316

$

122,520

$

247,836

$

370,154

$

352,097

$

722,251

Cost of revenue

64,629

67,044

189,190

196,053

Amortization of purchased intangible assets

1,473

2,779

4,160

7,871

Segment gross profit

59,214

52,697

111,911

176,804

148,173

324,977

Research and development and engineering

9,640

14,625

28,349

44,750

Selling, general and administrative

18,553

14,755

56,044

44,551

Amortization of purchased intangible assets

2,562

4,366

7,317

12,036

Restructuring, acquisition, and related costs

1,109

3,035

(
617

)

10,267

Segment operating income

27,350

15,916

43,266

85,711

36,569

122,280

Unallocated costs

—

—

(
21,418

)

—

—

(
53,100

)

Interest income (expense), net

—

—

(
6,014

)

—

—

(
17,473

)

Other income (expense), net

—

—

(
76

)

—

—

(
3,742

)

Income before income taxes

$

27,350

$

15,916

$

15,758

$

85,711

$

36,569

$

47,965

27

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

Three Months Ended September 27, 2024

Nine Months Ended September 27, 2024

Automation Enabling Technologies

Medical Solutions

Total

Automation Enabling Technologies

Medical Solutions

Total

Revenue

$

128,704

$

115,701

$

244,405

$

362,822

$

348,363

$

711,185

Cost of revenue

66,563

64,144

187,047

197,006

Amortization of purchased intangible assets

1,580

2,128

4,716

6,370

Segment gross profit

60,561

49,429

109,990

171,059

144,987

316,046

Research and development and engineering

8,860

14,519

28,834

41,686

Selling, general and administrative

18,016

13,774

55,404

40,211

Amortization of purchased intangible assets

2,813

3,776

8,410

10,836

Restructuring, acquisition, and related costs

809

1,037

2,898

1,764

Segment operating income

30,063

16,323

46,386

75,513

50,490

126,003

Unallocated costs

—

—

(
13,831

)

—

—

(
42,126

)

Interest income (expense), net

—

—

(
8,079

)

—

—

(
24,599

)

Other income (expense), net

—

—

(
251

)

—

—

(
1,007

)

Income before income taxes

$

30,063

$

16,323

$

24,225

$

75,513

$

50,490

$

58,271

Three

Months Ended

Nine Months Ended

September 26,

September 27,

September 26,

September 27,

Depreciation and Amortization Expenses

2025

2024

2025

2024

Automation Enabling Technologies

$

5,811

$

5,990

$

16,732

$

17,715

Medical Solutions

9,530

7,722

26,954

22,132

Unallocated

370

443

1,169

1,353

Total

$

15,711

$

14,155

$

44,855

$

41,200

September 26,

December 31,

2025

2024

Accounts Receivable

Automation Enabling Technologies

$

73,252

$

70,829

Medical Solutions

97,311

80,197

Total accounts receivable

$

170,563

$

151,026

Inventories

Automation Enabling Technologies

$

101,198

$

89,009

Medical Solutions

78,779

55,597

Total inventories

$

179,977

$

144,606

Total segment assets

$

350,540

$

295,632

28

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 26, 2025

(Unaudited)

Revenue by Geography
The Company aggregates geographic revenue based on the customer locations where products are shipped to. Revenue by geography was as follows (in thousands):

Three

Months Ended

Nine Months Ended

September 26,

September 27,

September 26,

September 27,

2025

2024

2025

2024

United States

$

130,423

$

124,328

$

382,187

$

364,800

Germany

27,097

33,559

82,832

98,659

Rest of Europe

36,661

30,584

103,289

94,083

China

24,293

24,623

67,504

60,708

Rest of Asia-Pacific

24,432

27,147

72,478

79,737

Other

4,930

4,164

13,961

13,198

Total

$

247,836

$

244,405

$

722,251

$

711,185

The majority of revenue from the Automation Enabling Technologies and Medical Solutions segments are generated from sales to customers within the United States and Europe.

Each segment also generates revenue across the other geographies, with no significant concentration of any segment’s remaining revenue.
Revenue by End Market
The Company primarily operates in 
two
 end markets: the medical market and the advanced industrial market. Revenue by end market was approximately as follows:

Three

Months Ended

Nine Months Ended

September 26,

September 27,

September 26,

September 27,

2025

2024

2025

2024

Medical

51

%

54

%

53

%

56

%

Advanced Industrial

49

%

46

%

47

%

44

%

Total

100

%

100

%

100

%

100

%

The majority of the revenue from the Automation Enabling Technologies segment is generated from sales to customers in the advanced industrial market. The majority of the revenue from the Medical Solutions segment is generated from sales to customers in the medical market.

29

I
tem 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with the Consolidated Financial Statements and Notes included in Item 1 of this Quarterly Report on Form 10-Q. The MD&A contains certain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. These forward-looking statements include, but are not limited to, our future financial results and financial condition; our belief that the Purchasing Managers Index (“PMI”) may provide an indication of the impact of general economic conditions on our sales into the advanced industrial end market; our strategy; drivers of revenue growth and our growth expectations in various markets; management’s plans and objectives for future operations, expenditures and product development, and investments in research and development; business prospects; potential of future product releases and expansion of our product and service offerings; industry trends; market conditions; our competitive positions; changes in economic and political conditions, including impacts from tariffs, supply chain disruptions and constraints and inflationary pressures; changes in accounting principles; changes in actual or assumed tax liabilities and tax law; expectations regarding tax exposures; anticipated reinvestment of future earnings, share repurchases and dividend policy; anticipated expenditures in regard to our benefit plans; future acquisitions and integration and anticipated benefits from acquisitions and dispositions; anticipated economic benefits and expected costs of restructuring programs; our ability to repay our indebtedness; our intentions regarding the use of cash; expectations regarding legal and regulatory requirements, including environmental requirements, and our compliance thereto; and other statements that are not historical facts.

Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various important factors, including, but not limited to, the following: economic and political conditions and the effects of these conditions on our customers’ businesses, capital expenditures and level of business activities; our dependence upon our ability to respond to fluctuations in product demand; our ability to continuously innovate, to introduce new products in a timely manner, and to manage transitions to new product innovations effectively; customer order timing and other similar factors; disruptions or breaches in security of our or our third-party providers’ information technology systems; risks associated with our operations in foreign countries; our increased use of outsourcing in foreign countries; risks associated with increased outsourcing of components manufacturing; our exposure to increased tariffs, trade restrictions or taxes on our products; our ability to contain or reduce costs; violations of our intellectual property rights and our ability to protect our intellectual property against infringement by third parties; risk of losing our competitive advantage; our failure to successfully integrate recent and future acquisitions into our business; our ability to attract and retain key personnel; our restructuring and realignment activities; product defects or problems integrating our products with other vendors’ products; disruptions in the supply of certain key components and other goods from our suppliers; our failure to accurately forecast component and raw material requirements leading to additional costs and significant delays in shipments; production difficulties and product delivery delays or disruptions; our exposure to extensive medical device regulations, which may impede or hinder the approval, certification or sale of our products and, in some cases, may ultimately result in an inability to obtain approval or certification of certain products or may result in the recall or seizure of previously approved or certified products; potential penalties for violating foreign and U.S. federal and state healthcare laws and regulations; impact of healthcare industry cost containment and healthcare reform measures; changes in governmental regulations related to our business or products; actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards, and other requirements; our failure to implement new information technology systems successfully; changes in foreign currency rates; our failure to realize the full value of our intangible assets; our reliance on original equipment manufacturer customers; the loss of sales, or significant reduction in orders from, any major customers; increasing scrutiny and changing expectations from investors, customers, governments and other stakeholders and third parties with respect to corporate sustainability policies and practices; the effects of climate change and related regulatory responses; our exposure to the credit risk of some of our customers and in weakened markets; being subject to U.S. federal income taxation even though we are a non-U.S. corporation; changes in tax laws and fluctuations in our effective tax rates; any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance our existing indebtedness, which may not be available on acceptable terms or at all; our existing indebtedness limiting our ability to engage in certain activities; volatility in the market price for our common shares; and our failure to maintain appropriate internal controls in the future. Other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition are discussed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 under the heading “Risk Factors”, as updated in our other filings with the Securities and Exchange Commission.
In this Quarterly Report on Form 10-Q, the words “expects,” “intends,” “anticipates,” “estimates,” “believes,” “future,” “plans,” “aims,” “would,” “could,” “should,” “potential,” “continues,” and similar words or expressions (as well as other words or expressions referencing future events, conditions, or circumstances) identify forward-looking statements. Readers should not place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Management and the Company disclaim any obligation to publicly update or revise any such forward-looking statements to reflect any changes in its expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required under applicable law.

30

Accounting Period

The interim consolidated financial statements of Novanta Inc. (the “Company”, “Novanta”, “we”, “us”, “our”) are prepared for each quarterly period ending on the Friday closest to the end of the calendar quarter, except for the fourth quarter which always ends on December 31.

Business Overview

We are a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers (“OEMs”) a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and advanced surgery with a proven ability to solve complex technical challenges. This enables us to engineer core components and sub-systems that deliver extreme precision and performance, tailored to our customers' demanding applications.
Reportable Segments
Reporting Segment Change
During the fourth quarter of 2024, we updated our organizational structure and re-aligned our financial reporting structure under two reportable segments: Automation Enabling Technologies and Medical Solutions. Prior to the reorganization, our historical reportable segments were: Precision Medicine and Manufacturing, Robotics and Automation, and Medical Solutions. Prior period segment financial information has been recast to align with the new reportable segments.
We operate in two reportable segments: Automation Enabling Technologies and Medical Solutions. The reportable segments and their principal activities are summarized below.

Automation Enabling Technologies
The Automation Enabling Technologies segment designs, manufactures and markets laser beam delivery components, laser beam delivery solutions, CO
2
 lasers, solid state lasers, ultrafast lasers, optical and inductive encoders, precision motors, integrated stepper motors, servo drives, motion control solutions, intelligent robotic end-of-arm technology solutions, and air bearing spindles to customers worldwide. The segment serves highly demanding applications for advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures such as ophthalmology applications. The vast majority of the segment’s product offerings are sold to OEM customers. The segment sells the majority of these products directly, utilizing a highly technical sales force, and also sells some indirectly, through resellers and distributors.

Medical Solutions

The Medical Solutions segment designs, manufactures and markets a range of medical grade technologies, including medical insufflators and endoscopic pumps and related disposables, laser beam delivery solutions, video processing and streaming and capture, machine vision technologies, radio frequency identification (“RFID”) technologies, barcode identification technologies, thermal chart recorders, light and color measurement technologies, touch panel displays, and advanced motion control solutions. The vast majority of the segment’s product offerings are sold to OEM customers. The segment sells the majority of these products directly, utilizing a highly technical sales force, and also sells some indirectly, through resellers and distributors.
End Markets
We primarily operate in two end markets: the medical market and the advanced industrial market.

Medical Market
For the nine months ended September 26, 2025, the medical market accounted for approximately 53% of our revenue. Revenue from our products sold to the medical market is generally affected by hospital, life science, and other healthcare provider capital spending, growth rates of surgical procedures, changes in regulatory requirements and laws, demand level for life science automation technology, aggregation of purchasing by healthcare networks, changes in technology requirements, timing of OEM customers’ product development and new product launches, changes in customer or patient preferences, and general demographic trends.

31

Advanced Industrial Market
For the nine months ended September 26, 2025, the advanced industrial market accounted for approximately 47% of our revenue. Revenue from our products sold to the advanced industrial market is affected by a number of factors, including changing technology requirements and preferences of our customers, productivity or quality investments in a manufacturing environment, the financial conditions of our customers, changes in regulatory requirements and laws, and general economic conditions. We believe that the PMI on manufacturing activities specific to different regions around the world may provide an indication of the impact of general economic conditions on our sales into the advanced industrial market.

Strategy

Our strategy is to drive sustainable, profitable growth through short-term and long-term initiatives, including:

•
disciplined focus on our diversified business model of providing functionality to long life-cycle OEM customer platforms in attractive medical and advanced industrial niche markets;
•
improving our business mix to increase medical sales as a percentage of total revenue by:
-
introducing new products aimed at attractive medical applications, such as minimally invasive and robotic surgery, ophthalmology, patient monitoring, drug delivery, clinical laboratory testing and life science equipment; 
-
deepening our key account management relationships with and driving cross selling of our product offerings to leading medical equipment manufacturers; and 
-
pursuing complementary medical technology acquisitions;
•
increasing our penetration of high growth advanced industrial applications, such as laser materials processing, intelligent end-of-arm robotic technology solutions, robotics, laser additive manufacturing, automation and metrology, by working closely with OEM customers to launch application specific products that closely match the requirements of each application;
•
broadening our portfolio of enabling proprietary technologies and capabilities through increased investment in new product development, and investments in application development to further penetrate existing customers, while expanding the applicability of our solutions to new markets;
•
broadening our product and service offerings through the acquisition of innovative and complementary technologies and solutions in medical and advanced industrial technology applications;
•
expanding sales and marketing channels to reach new target customers;
•
improving our existing operations to expand profit margins and improve customer satisfaction by implementing lean manufacturing principles, strategic sourcing across our major production sites, and optimizing and limiting the growth of our fixed cost base; and 
•
attracting, retaining, and developing world-class talented and motivated employees. 
Significant Events and Updates

Acquisition of Keonn Technologies, S.L.
On April 8, 2025, we acquired 100% of the outstanding stock of Keonn Technologies, S.L. (“Keonn”), a Barcelona, Spain-based leader in Radio-Frequency Identification (“RFID”) solutions for a purchase price of €64.8 million ($71.0 million), net of cash acquired, including €4.1 million ($4.5 million) estimated fair value of contingent consideration and €2.0 million ($2.2 million) related to a purchase price holdback. The purchase includes up to €20.0 million ($21.9 million) in contingent consideration payable upon the achievement of certain revenue targets through December 2027. In addition, we have granted equity totaling €9.0 million ($9.9 million) to Keonn employees. Keonn is included in the Medical Solutions segment.
Fourth Amended and Restated Credit Agreement
On June 27, 2025, we entered into the Fourth Amended and Restated Credit Agreement. The Fourth Amended and Restated Credit Agreement amends and restates, in its entirety, the Third Amended and Restated Credit Agreement dated as of December 31, 2019 (the “Third Agreement”). The Fourth Amended and Restated Credit Agreement provides for an aggregate credit facility of approximately $1.0 billion, comprised of a €65.3 million euro-denominated 5-year term loan facility (the “Euro Term Loans”), a $75.0 million U.S. dollar denominated 5-year term loan facility (the “U.S. Term Loans”), and an $850.0 million 5-year revolving credit facility (the “Revolving Facility”, and together with the Euro Term Loans and the U.S. Term Loans, collectively, the “Senior Credit

32

Facilities”). The Senior Credit Facilities mature in June 2030 and include an uncommitted “accordion” feature pursuant to which the commitments thereunder may be increased by an additional $350.0 million in aggregate, subject to the satisfaction of certain customary conditions.

Business Environment
In recent years, the global economy has faced significant challenges, including inflation, supply chain disruptions, business slowdowns, labor shortages, and market volatility, and recently new and proposed tariffs announced by the U.S. Presidential Administration have introduced additional uncertainty. We address macroeconomic challenges by continuing to execute our strategy. There have been improvements in the supply chain with better on-time deliveries, and recent efforts have successfully addressed talent shortages. However, uncertainty remains about overall macroeconomic conditions due to geopolitical tensions and changes in trade policies.

Economic tensions and changes in trade policies, such as higher tariffs, retaliatory measures, renegotiated free trade agreements, changes in government funding, and the ongoing impact from prolonged inflationary pressures have impacted the global market for our products and the cost to manufacture.

Results of Operations for the Three and Nine Months Ended September 26, 2025 Compared with the Three and Nine Months Ended September 27, 2024
Overview of Financial Results

Total revenue of $247.8 million for the three months ended September 26, 2025 increased $3.4 million, or 1.4%, from the prior year period primarily due to revenue from our current year acquisition, partially offset by a decrease in revenue in the Automation Enabling Technologies segment and a decrease in revenue in the Medical Solutions segment excluding the impact of current year acquisition. The net effect of our acquisition resulted in an increase in revenue of $8.4 million, or 3.4%. In addition, foreign currency exchange rates favorably impacted our revenue by $4.4 million, or 1.8%, for the three months ended September 26, 2025.
Total revenue of $722.3 million for the nine months ended September 26, 2025 increased $11.1 million, or 1.6%, from the prior year period, primarily due to revenue from our current year acquisition and an increase in revenue in the Automation Enabling Technologies segment, partially offset by a decrease in revenue in the Medical Solutions segment excluding the impact of current year acquisition. The net effect of our acquisition resulted in an increase in revenue of $13.7 million, or 1.9%. In addition, foreign currency exchange rates favorably impacted our revenue by $7.6 million, or 1.1%, for the nine months ended September 26, 2025.
Operating income of $21.8 million for the three months ended September 26, 2025 decreased $10.7 million, or 32.9%, from the prior year period. This decrease was attributable to an increase in selling, general and administrative expenses of $7.1 million, an increase in restructuring, acquisition and related costs of $4.2 million, and an increase in research and development and engineering expenses of $0.8 million, partially offset by an increase in gross profit of $1.7 million.
Operating income of $69.2 million for the nine months ended September 26, 2025 decreased $14.7 million, or 17.5%, from the prior year period. This decrease was attributable to an increase in selling, general and administrative expenses of $11.4 million, an increase in restructuring, acquisition and related costs of $9.5 million, and an increase in research and development and engineering expenses of $2.4 million, partially offset by an increase in gross profit of $8.7 million.

Basic earnings per common share (“Basic EPS”) of $0.30 for the three months ended September 26, 2025 decreased $0.23 from the prior year period. Diluted earnings per common share (“Diluted EPS”) of $0.30 for the three months ended September 26, 2025 decreased $0.23 from the prior year period. The decreases were primarily due to a decrease in operating income.
Basic earnings per common share (“Basic EPS”) of $1.01 for the nine months ended September 26, 2025 decreased $0.32 from the prior year period. Diluted earnings per common share (“Diluted EPS”) of $1.01 for the nine months ended September 26, 2025 decreased $0.31 from the prior year period. The decreases were primarily due to a decrease in operating income and an increase in foreign exchange transaction losses, partially offset by a decrease in interest expense.

33

Revenue
The following tables set forth external revenue by reportable segment for the periods noted (dollars in thousands):

Three Months Ended

September 26,

September 27,

Increase

Percentage

2025

2024

(Decrease)

Change

Automation Enabling Technologies

$

125,316

$

128,704

$

(3,388

)

(2.6

)%

Medical Solutions

122,520

115,701

6,819

5.9

%

Total

$

247,836

$

244,405

$

3,431

1.4

%

Nine Months Ended

September 26,

September 27,

Increase

Percentage

2025

2024

(Decrease)

Change

Automation Enabling Technologies

$

370,154

$

362,822

$

7,332

2.0

%

Medical Solutions

352,097

348,363

3,734

1.1

%

Total

$

722,251

$

711,185

$

11,066

1.6

%

Automation Enabling Technologies
Automation Enabling Technologies segment revenue for the three months ended September 26, 2025 decreased $3.4 million, or 2.6%, versus the prior year period, primarily due to a decrease in demand in precision manufacturing products.
Automation Enabling Technologies segment revenue for the nine months ended September 26, 2025 increased $7.3 million, or 2.0% versus the prior year period, primarily due to increased demand in robotics and automation products, partially offset by a decrease in demand in precision manufacturing products.

Medical Solutions
Medical Solutions segment revenue for the three months ended September 26, 2025 increased $6.8 million, or 5.9%, versus the prior year period, primarily due to the net impact of $8.4 million revenue contributions from the current year acquisition, and an increase in sales of advanced surgery products, partially offset by a decrease in sales of precision medicine products.

Medical Solutions segment revenue for the nine months ended September 26, 2025 increased $3.7 million, or 1.1%, versus the prior year period, primarily due to the net impact of $13.7 million revenue contributions from the current year acquisition, and an increase in sales of advanced surgery products, partially offset by a decrease in sales of precision medicine products.

Gross Profit and Gross Profit Margin

The following table sets forth the gross profit and gross profit margin for each of our reportable segments for the periods noted (dollars in thousands):

Three

Months Ended

Nine Months Ended

September 26,

September 27,

September 26,

September 27,

2025

2024

2025

2024

Gross profit:

Automation Enabling Technologies

$

59,214

$

60,561

$

176,804

$

171,059

Medical Solutions

52,697

49,429

148,173

144,987

Unallocated

(990

)

(775

)

(2,956

)

(2,726

)

Total

$

110,921

$

109,215

$

322,021

$

313,320

Gross profit margin:

Automation Enabling Technologies

47.3

%

47.1

%

47.8

%

47.1

%

Medical Solutions

43.0

%

42.7

%

42.1

%

41.6

%

Total

44.8

%

44.7

%

44.6

%

44.1

%

Gross profit and gross profit margin can be influenced by a number of factors, including product mix, pricing, volume, manufacturing efficiencies and utilization, costs for raw materials and outsourced manufacturing, trade tariffs, freight costs, headcount, inventory excess and obsolescence, and warranty expenses.

34

Automation Enabling Technologies
Automation Enabling Technologies segment gross profit for the three months ended September 26, 2025 decreased $1.3 million, or 2.2%, versus the prior year period, primarily due to a decrease in revenue. Automation Enabling Technologies segment gross profit margin was 47.3% for the three months ended September 26, 2025, versus a gross profit margin of 47.1% for the prior year period.

Automation Enabling Technologies segment gross profit for the nine months ended September 26, 2025 increased $5.7 million, or 3.4%, versus the prior year period, primarily due to an increase in both revenue and gross profit margin. Automation Enabling Technologies segment gross profit margin was 47.8% for the nine months ended September 26, 2025, versus a gross profit margin of 47.1% for the prior year period. The increase in gross profit margin was primarily attributable to factory productivity improvement and favorable product mix, partially offset by higher tariff costs.
Medical Solutions
Medical Solutions segment gross profit for the three months ended September 26, 2025 increased

$3.3 million, or 6.6%, versus the prior year period, primarily due to an increase in both revenue and gross profit margin. Medical Solutions segment gross profit margin was 43.0% for the three months ended September 26, 2025, versus a gross profit margin of 42.7% for the prior year period. The increase in gross profit margin was primarily due to factory productivity improvements.

Medical Solutions segment gross profit for the nine months ended September 26, 2025 increased

$3.2 million, or 2.2%, versus the prior year period, primarily due to an increase in both revenue and gross profit margin. Medical Solutions segment gross profit margin was 42.1% for the nine months ended September 26, 2025, versus a gross profit margin of 41.6% for the prior year period. The increase in gross profit margin was primarily due to factory productivity improvements, a prior year one-time inventory related charge associated with a product line closure, and a prior year amortization of inventory fair value adjustment associated with our 2024 acquisition.

Operating Expenses

The following table sets forth operating expenses for the periods noted (in thousands):

Three

Months Ended

Nine Months Ended

September 26,

September 27,

September 26,

September 27,

2025

2024

2025

2024

Research and development and engineering

$

24,090

$

23,253

$

72,617

$

70,230

Selling, general and administrative

51,378

44,319

144,077

132,642

Amortization of purchased intangible assets

6,928

6,589

19,353

19,246

Restructuring, acquisition, and related costs

6,677

2,499

16,794

7,325

Total

$

89,073

$

76,660

$

252,841

$

229,443

Research and Development and Engineering Expenses

Research and Development and Engineering (“R&D”) expenses are primarily comprised of employee compensation related expenses and cost of materials for R&D projects. R&D expenses were $24.1 million, or 9.7% of revenue, during the three months ended September 26, 2025, versus $23.3 million, or 9.5% of revenue, during the prior year period.

R&D expenses were $72.6 million, or 10.1% of revenue, during the nine months ended September 26, 2025, versus $70.2 million, or 9.9% of revenue, during the prior year period. The increase in R&D expenses, both in total dollars and percentage of revenue, was primarily driven by higher spending on projects related to new product introductions and increased costs from the current year acquisition.
Selling, General and Administrative Expenses
Selling, general and administrative (“SG&A”) expenses include costs for sales and marketing, sales administration, finance, human resources, legal, information systems, and executive management functions. SG&A expenses were $51.4 million, or 20.7% of revenue, during the three months ended September 26, 2025, versus $44.3 million, or 18.1% of revenue, during the prior year period. The increase in SG&A expenses, both in total dollars and as a percentage of revenue, was primarily driven by costs associated with planning and design phase of our enterprise resource planning (“ERP”) system implementation, costs associated with an officer transition, costs incurred in connection with an insurance recovery claim, and increased costs from the current year acquisition.

35

SG&A expenses were $144.1 million, or 19.9% of revenue, during the nine months ended September 26, 2025, versus $132.6 million, or 18.7% of revenue, during the prior year period. The increase in SG&A expenses, both in total dollars and as a percentage of revenue, was primarily driven by costs associated with planning and design phase of our ERP system implementation, costs associated with an officer transition, costs incurred in connection with an insurance recovery claim, and increased costs from the current year acquisition.
Amortization of Purchased Intangible Assets

Amortization of purchased intangible assets, excluding amortization of developed technologies which is included in cost of revenue, was $6.9 million, or 2.8% of revenue, during the three months ended September 26, 2025, versus $6.6 million, or 2.7% of revenue, during the prior year period.

Amortization of purchased intangible assets, excluding amortization of developed technologies which is included in cost of revenue, was $19.4 million, or 2.7% of revenue, during the nine months ended September 26, 2025, versus $19.2 million, or 2.7% of revenue, during the prior year period.
Restructuring, Acquisition, and Related Costs
We recorded restructuring, acquisition, and related costs of $6.7 million during the three months ended September 26, 2025, versus $2.5 million during the prior year period. The increase in restructuring, acquisition and related costs was primarily due to expenses related to the 2025 restructuring program.
We recorded restructuring, acquisition, and related costs of $16.8 million during the nine months ended September 26, 2025, versus $7.3 million during the prior year period. The increase in restructuring, acquisition and related costs was primarily due to expenses related to the 2025 restructuring program, and an increase in acquisition and related expenses related to our current year acquisition, partially offset by a gain on the sale of an owned facility.
Operating Income (Loss) by Segment

The following table sets forth operating income (loss) by segment for the periods noted (in thousands):

Three Months Ended

Nine Months Ended

September 26,

September 27,

September 26,

September 27,

2025

2024

2025

2024

Operating Income (Loss)

Automation Enabling Technologies

$

27,350

$

30,063

$

85,711

$

75,513

Medical Solutions

15,916

16,323

36,569

50,490

Unallocated

(21,418

)

(13,831

)

(53,100

)

(42,126

)

Total

$

21,848

$

32,555

$

69,180

$

83,877

Automation Enabling Technologies
Automation Enabling Technologies segment operating income was $27.4 million, or 21.8% of revenue, during the three months ended September 26, 2025, versus $30.1 million, or 23.4% of revenue, during the prior year period. The decrease in operating income was primarily due to a decrease in gross profit of $1.3 million, an increase in R&D expenses of $0.8 million, and an increase in SG&A expenses of $0.5 million.
Automation Enabling Technologies segment operating income was $85.7 million, or 23.2% of revenue, during the nine months ended September 26, 2025, versus $75.5 million, or 20.8% of revenue, during the prior year period. The increase in operating income was primarily due to an increase in gross profit of $5.7 million, a decrease in restructuring, acquisition and related costs of $3.5 million, and a decrease in amortization expenses of $1.1 million.
Medical Solutions
Medical Solutions segment operating income was $15.9 million, or 13.0% of revenue, during the three months ended September 26, 2025, versus $16.3 million, or 14.1% of revenue, during the prior year period. The decrease in operating income was primarily due to an increase in restructuring, acquisition and related costs of $2.0 million, an increase in SG&A expenses of $1.0 million, and an increase in amortization expenses of $0.6 million, partially offset by an increase in gross profit of $3.3 million.

36

Medical Solutions segment operating income was $36.6 million, or 10.4% of revenue, during the nine months ended September 26, 2025, versus $50.5 million, or 14.5% of revenue, during the prior year period. The decrease in operating income was primarily due to an increase in restructuring, acquisition and related costs of $8.5 million, an increase in SG&A expenses of $4.3 million, an increase in R&D expenses of $3.1 million, and an increase in amortization expenses of $1.2 million, partially offset by an increase in gross profit of $3.2 million.

Unallocated
Unallocated costs primarily represent costs of corporate and shared services functions that are not allocated to the operating segments, including certain restructuring and most acquisition costs. These costs for the three months ended September 26, 2025 increased

$7.6 million versus the prior year period. The increase in operating loss was primarily driven by costs associated with planning and design phase of our ERP system implementation, costs incurred in connection with an insurance recovery claim and officer transition costs.

These costs for the nine months ended September 26, 2025 increased

$11.0 million versus the prior year period. The increase in operating loss was primarily driven by costs associated with planning and design phase of our ERP system implementation, officer transition costs, costs incurred in connection with an insurance recovery claim and costs associated with 2025 restructuring programs.
Other Income and Expense Items

The following table sets forth other income and expense items for the periods noted (in thousands):

Three

Months Ended

Nine Months Ended

September 26,

September 27,

September 26,

September 27,

2025

2024

2025

2024

Interest income (expense), net

$

(6,014

)

$

(8,079

)

$

(17,473

)

$

(24,599

)

Foreign exchange transaction gains (losses), net

14

(202

)

(3,098

)

(787

)

Other income (expense), net

(90

)

(49

)

(644

)

(220

)

Interest Income (Expense), Net

Net interest expense was $6.0 million for the three months ended September 26, 2025, versus $8.1 million for the prior year period. The decrease in net interest expense was primarily due to a decrease in the average debt levels under our senior credit facilities and a decrease in the weighted average interest rate. The weighted average interest rate on our senior credit facilities was 5.32% during the three months ended September 26, 2025, versus 6.83% during the prior year period.
Net interest expense was $17.5 million for the nine months ended September 26, 2025, versus $24.6 million for the prior year period. The decrease in net interest expense was primarily due to a decrease in the average debt levels under our senior credit facilities and a decrease in the weighted average interest rate. The weighted average interest rate on our senior credit facilities was 5.48% during the nine months ended September 26, 2025, versus 6.68% during the prior year period.
Foreign Exchange Transaction Gains (Losses), Net

Foreign exchange transaction gains (losses) were less than $0.1 million for the three months ended September 26, 2025 versus $(0.2) million for the prior year period.

Foreign exchange transaction gains (losses) were $(3.1) million for the nine months ended September 26, 2025 and $(0.8) million for the prior year period. The increase in net foreign exchange transaction losses was primarily due to changes in the value of the U.S. Dollar against the British Pound and Euro, and realized losses on foreign currency contracts.

Other Income (Expense), Net

Net other expense was nominal for the three and nine months ended September 26, 2025 and the three and nine months ended September 27, 2024.

37

Income Tax Provision (Benefit)
Our effective tax rate for the three months ended September 26, 2025 was 32.4%, versus 20.8% for the prior year period. Our effective tax rate of 32.4% for the three months ended September 26, 2025 differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated U.S. tax benefits for Foreign Derived Intangible Income (“FDII”) and R&D tax credits, and U.K. patent box deductions; partially offset by various non-deductible transaction-related and compensation expenses and uncertain tax position accruals.

Our effective tax rate for the three months ended September 27, 2024 of 20.8% differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated deductions for FDII, U.K. patent box deductions and R&D tax credits, partially offset by disallowed compensation deductions, uncertain tax position accruals, and Pillar Two inclusion.
Our effective tax rate for the nine months ended September 26, 2025 was 24.2%, versus 18.3% for the prior year period. Our effective tax rate of 24.2% for the nine months ended September 26, 2025 differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated U.S. tax benefits for FDII and R&D tax credits, and U.K. patent box deductions; partially offset by various non-deductible transaction-related and compensation expenses and uncertain tax position accruals.
Our effective tax rate of 18.3% for the nine months ended September 27, 2024 differs from the Canadian statutory tax rate of 29.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, estimated deductions for FDII, U.K. patent box deductions, R&D tax credits and windfall tax benefits upon vesting of certain share-based compensation awards, partially offset by disallowed compensation deductions, uncertain tax position accruals, and Pillar Two inclusion. For the nine months ended September 27, 2024, the tax benefits upon vesting of certain share-based compensation awards had a benefit of 3.1% on our effective tax rate.
On December 12, 2022, the EU member states agreed to implement the Organization for Economic Co-operation and Development’s (“OECD”) Pillar Two Model Rules. These rules, which impose a global corporate minimum income tax rate of 15%, have been enacted or introduced in proposed legislation in numerous countries worldwide, including many jurisdictions in which we operate. Additional countries are actively considering changes to their tax laws to adopt certain parts of the OECD’s proposals. We fall under the transitional safe harbor rules in the majority of jurisdictions in which we operate and are therefore not subject to Pillar Two global minimum tax in those jurisdictions. Where we cannot apply the safe harbor rules, we have estimated the impact of this minimum tax in our effective tax rate analysis. We continue to closely monitor the progression of legislative activities.
On July 4, 2025, the U.S. enacted H.R.1 - One Big Beautiful Bill Act (the “Act”). The Act contains numerous income tax provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act and modifications to the international tax framework. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. We continue to evaluate the implications of the Act on our consolidated financial statements and related disclosures. We included an estimated impact of items affecting our income tax expense for the three and nine months ended September 26, 2025.
Liquidity and Capital Resources

We assess our liquidity in terms of our ability to generate cash to fund our operating, investing, and financing activities. Our primary ongoing cash requirements are funding operations, capital expenditures, investments in businesses, and repayment of our debt and related interest payments. Our primary sources of liquidity are cash flows from operations and borrowings under our revolving credit facility. We believe our future operating cash flows will be sufficient to meet our future operating and capital expenditure cash needs for the foreseeable future, including at least the next 12 months. The availability of borrowing capacity under our revolving credit facility provides another potential source of liquidity for any future capital expenditures and other liquidity needs. In addition, we have the ability to expand our borrowing capacity by up to $350.0 million by exercising the accordion option under our revolving credit agreement. We may also seek to raise additional capital, which could be in the form of bonds, convertible debt or preferred or common equity, to fund business development activities or other future investing cash requirements, subject to approval by the lenders in the Fourth Amended and Restated Credit Agreement (as amended, the “Credit Agreement”). There is no assurance that such capital will be available on reasonable terms or at all.
Significant factors affecting the management of our ongoing cash requirements are the adequacy of available bank lines of credit and our ability to attract long term capital with satisfactory terms. The sources of our liquidity are subject to all of the risks of our business and could be adversely affected by, among other factors, risks associated with events outside of our control, such as economic consequences of geopolitical conflicts, monetary, fiscal, tax or trade policy changes in the U.S. and other countries and their impact on the global financial markets, a decrease in demand for our products, our ability to integrate current and future acquisitions,

38

deterioration in certain financial ratios, availability of borrowings under our revolving credit facility, and other market changes in general. See “Risks Relating to Our Common Shares and Our Capital Structure” included in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Our cash requirements primarily consist of principal and interest payments associated with our Senior Credit Facilities (as defined below), operating and finance leases, purchase commitments, and pension obligations. Such contractual obligations are described in our Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to Consolidated Financial Statements, each included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Our ability to make payments on our indebtedness and to fund our operations may be dependent upon the operating income and the distribution of funds from our subsidiaries. However, as local laws and regulations and/or the terms of our indebtedness restrict certain of our subsidiaries from paying dividends and transferring assets to us, there is no assurance that our subsidiaries will be permitted to provide us with sufficient dividends, distributions or loans when necessary.
As of September 26, 2025, $58.0 million of our $89.2 million cash and cash equivalents was held by subsidiaries outside of Canada and the U.S.

Generally, our intent is to use cash held in these foreign subsidiaries to fund our local operations or acquisitions by those local subsidiaries and to pay down borrowings under our Senior Credit Facilities. Approximately $162.9 million of our outstanding term loan and revolver borrowings under our Senior Credit Facilities were held in our subsidiaries outside of Canada and the U.S. as of September 26, 2025. Additionally, we may use intercompany loans to address short-term cash flow needs for various subsidiaries.

Senior Credit Facilities

On June 27, 2025, we entered into the Fourth Amended and Restated Credit Agreement (the “Credit Agreement”), consisting of a €65.3 million euro-denominated 5-year term loan facility (the “Euro Term Loans”, a $75.0 million U.S. Dollar denominated 5-year term loan facility (the “U.S. Term Loans”), and an $850.0 million 5-year revolving credit facility (the “Revolving Facility”, and together with the Euro Term Loans and the U.S. Term Loans, collectively, the “Senior Credit Facilities”). The Senior Credit Facilities mature in June 2030 and include an uncommitted “accordion” feature pursuant to which the commitments thereunder may be increased by an additional $350.0 million in aggregate, subject to the satisfaction of certain customary conditions.

The term loan facilities require quarterly scheduled principal repayments of €1.1 million beginning in September 2025 (with respect to the Euro Term Loans), and $0.5 million beginning in September 2026, increasing to $0.9 million in September 2027 (with respect the U.S. Term Loans), with the remaining principal balance of the term loans due on June 27, 2030, if the maturity date of the term loan facility is not otherwise extended. We may make additional principal payments at any time, which will reduce the next quarterly installment payment due. We may pay down outstanding borrowings under our revolving credit facility with cash on hand and cash generated from future operations at any time.
As of September 26, 2025, we had $150.4 million term loans and $306.6 million revolver borrowings outstanding under our Senior Credit Facilities. Borrowings under the Credit Agreement bear interest at the Base Rate (as defined in the Credit Agreement) plus a margin ranging between zero and 0.75% per annum, determined by reference to the our consolidated leverage ratio, or SOFR, SONIA or EURIBOR, as applicable, plus a margin ranging between 1.00% and 1.75% per annum, determined by reference to our consolidated leverage ratio. In addition, we are obligated to pay a commitment fee on the unused portion of the Revolving Facility. As of September 26, 2025, we had outstanding borrowings under the Credit Agreement denominated in Euro and U.S. dollars of $162.9 million and $294.1 million, respectively.
The Credit Agreement contains various covenants that we believe are usual and customary for this type of agreement, including a maximum consolidated leverage ratio and a minimum consolidated fixed charge coverage ratio (as defined in the Credit Agreement). The following table summarizes these financial covenants and our compliance therewith as of September 26, 2025:

Requirement

Actual

Maximum consolidated leverage ratio 
(1)

3.50

1.89

Minimum consolidated fixed charge coverage ratio

1.25

5.65

(1)
 Maximum consolidated leverage ratio shall be increased to 4.00 for four consecutive quarters following a designated acquisition, as defined in the Fourth Amended and Restated Credit Agreement.
Share Repurchase Plans
Our Board of Directors may approve share repurchase plans from time to time. Under these repurchase plans, shares may be repurchased at our discretion based on the ongoing assessment of the capital needs of the business, the market price of our common

39

shares, and general market conditions. Shares may also be repurchased through an accelerated share purchase agreement, on the open market or in privately negotiated transactions in accordance with applicable federal securities laws. Repurchases may be made under certain SEC regulations, which would permit common shares to be repurchased when we would otherwise be prohibited from doing so under insider trading laws. While the share repurchase plans are generally intended to offset dilution from equity awards granted to our employees and directors, the plans do not obligate us to acquire any particular amount of common shares. No time limit is typically set for the completion of the share repurchase plans, and the plans may be suspended or discontinued at any time. We expect to fund share repurchases through cash on hand and cash generated from operations.
In February 2020, our Board of Directors approved a share repurchase plan (the “2020 Repurchase Plan”) authorizing the repurchase of $50.0 million worth of common shares. Share repurchases have been made under the 2020 Repurchase Plan pursuant to Rule 10b-18 under the Securities Exchange Act of 1934. We repurchased 179 thousand shares under the 2020 Repurchase Plan for an aggregate purchase price of $21.1 million and average price of $118.09 per share during the nine months ended September 26, 2025. We had $28.4 million available for share repurchases under the 2020 Repurchase Plan as of September 26, 2025.

In September 2025, our Board of Directors approved a new share repurchase plan (the “2025 Repurchase Plan”) authorizing the repurchase of an additional $200.0 million worth of common shares. The 2025 Repurchase Plan does not obligate the Company to acquire any particular amount of common shares. No time limit was set for the completion of the 2025 Repurchase Plan, and the plan may be suspended or discontinued at any time. No shares have been repurchased under the 2025 Repurchase Plan to date.
Cash Flows for the Nine Months Ended September 26, 2025 and September 27, 2024

The following tables summarize our cash flows, cash and cash equivalents, and unused and available funds under our revolving credit facility for the periods indicated (in thousands):

Nine Months Ended

September 26,

September 27,

2025

2024

Net cash provided by operating activities

$

55,251

$

96,950

Net cash used in investing activities

$

(70,709

)

$

(206,113

)

Net cash provided by financing activities

$

(11,319

)

$

92,559

September 26,

December 31,

2025

2024

Cash and cash equivalents

$

89,221

$

113,989

Unused and available funds under the revolving credit facility

$

543,387

$

346,249

Operating Cash Flows

Cash provided by operating activities was $55.3 million for the nine months ended September 26, 2025, versus $97.0 million for the prior year period. Cash provided by operating activities for the nine months ended September 26, 2025 decreased from the prior year period primarily as a result of an increase in inventory and higher cash paid for income taxes.
Investing Cash Flows

Cash used in investing activities was $70.7 million for the nine months ended September 26, 2025, primarily driven by $64.3 million of cash consideration (net of cash acquired) paid for our 2025 acquisition and $12.0 million for capital expenditures, partially offset by $5.5 million of cash received from the sale of properties.
Cash used in investing activities was $206.1 million for the nine months ended September 27, 2024, primarily driven by $191.2 million of cash consideration (net of cash acquired) paid for our 2024 acquisition and $14.9 million for capital expenditures.

We expect to use an aggregate of approximately $15 million to $20 million in 2025 for capital expenditures related to investments in new property, plant and equipment for our existing businesses.
Financing Cash Flows

Cash provided by financing activities was $11.3 million for the nine months ended September 26, 2025, primarily driven by $72.8 million of borrowings under our revolving credit facility to fund our 2025 acquisition, partially offset by $49.2 million of term loan and revolving credit facility repayments, $20.2 million related to the repurchase of common shares and $7.7 million of payroll tax payments upon vesting of share-based compensation awards.

40

Cash provided by financing activities was $92.6 million for the nine months ended September 27, 2024, primarily driven by $198.0 million of borrowings under our revolving credit facility to fund our 2024 acquisition, partially offset by $96.0 million of term loan and revolving credit facility repayments and $8.9 million of payroll tax payments upon vesting of share-based compensation awards.

Critical Accounting Policies and Estimates

The critical accounting policies that we believe impact significant judgments and estimates used in the preparation of our consolidated financial statements presented in this periodic report on Form 10-Q are described in our Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to Consolidated Financial Statements, each included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. There have been no material changes to our critical accounting policies and estimates through September 26, 2025 from those disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
Recent Accounting Pronouncements

See Note 1 to Unaudited Interim Consolidated Financial Statements.

Item 3. Quant
itative and Qualitative Disclosures About Market Risk

Our primary market risk exposures are foreign currency exchange rate fluctuations and interest rate sensitivity. During the three months ended September 26, 2025, there have been no material changes to the information included under Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

I
tem 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15(b) under the Securities and Exchange Act of 1934 (the “Exchange Act”), our management carried out an evaluation, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of September 26, 2025, the end of the period covered by this report. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 26, 2025.

Changes in Internal Control Over Financial Reporting

There has been no change to our internal control over financial reporting during the fiscal quarter ended September 26, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

41

P
ART II—OTHER INFORMATION

I
tem 1. Legal Proceedings

We are subject to various legal proceedings and claims that arise in the ordinary course of business. We do not believe that the outcome of these claims will have a material adverse effect upon our financial condition or results of operations but there can be no assurance that any such claims, or any similar claims, would not have a material adverse effect upon our financial condition or results of operations.
I
tem 1A. Risk Factors

Our operations and financial results are subject to various risks and uncertainties, including the factors discussed in Part I, Item 1A, Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2024, which could adversely affect our business, financial conditions and future results. Other than the risk factor set forth below, there have been no material changes from the risk factors discussed in our Annual Report.
Our results of operations could be adversely affected by economic and political conditions and the effects of these conditions on our customers’ businesses, capital expenditures and levels of business activities.

A large portion of our product sales are dependent on our customers’ need for increased capacity, productivity and cost saving initiatives, improved product quality and performance, and new investments. Weaknesses in our end markets could negatively impact our revenue and gross margin and consequently have a material adverse effect on our business, financial condition and results of operations. A severe and/or prolonged overall economic downturn or a negative or uncertain political climate could lead to weaknesses in our end markets and adversely affect our customers’ financial condition and the timing or levels of our customers’ capital expenditures or business activities. We have experienced significant cyclical end market fluctuations in the past. For example, diminished growth expectations, economic and political uncertainty in regions across the globe and effects of the COVID-19 pandemic adversely impacted our customers’ financial condition and ability to maintain product order levels and reduced the demand for our products in 2020, and other pandemics and public health crises could have similar consequences. Political conditions, including new and changing laws or tariffs, regulations, government funding, executive orders and enforcement priorities, may impact customer budgets and create uncertainty about how such laws and regulations will be interpreted and applied, which may impact customer demand and adversely impact our business. For example, changes in the regulatory environment affecting life sciences, bioprocessing, and pharmaceutical companies, and reduced headcount and budget allocations to government agencies that fund research and development activities, such as the U.S. Food and Drug Administration (“FDA”), U.S. National Institutes of Health (“NIH”), or targeted headcount reductions or cancellations of certain grants or contracts by the U.S. federal government, could adversely affect our business or results of operations. In addition, certain sub-segments of the advanced industrial market that we serve, including the microelectronics and industrial capital equipment sector, are cyclical and have historically experienced periods of oversupply, resulting in downturns in demand for capital equipment in which many of our products are used. It is difficult to predict the timing, length and severity of these downturns and their impact on our business. Further, our order levels or results of operations for a given period may not be indicative of order levels or results of operations for subsequent periods. For the foreseeable future, our operations will continue to depend upon industries that are subject to market cycles which, in turn, could adversely affect the market demand for our products.
We have also faced increases in inflationary conditions in materials and components. These inflationary conditions have caused us to increase prices; however, such price increases may not be accepted by our customers or may not adequately offset the increases in our costs, thereby negatively affecting our results of operations. Changes in global economic conditions, including inflationary conditions, could also shift demand for products or services for which we do not have competitive advantages. This could negatively affect the amount of business that we are able to obtain. In addition, if we are unable to successfully anticipate changes in economic and political conditions, we may be unable to effectively plan for and respond to those changes, and our business could be negatively affected.

42

I
tem 2. Unregistered Sales of Equity Securities and Use of Proceeds
The following table sets forth certain information with respect to repurchases of the Company’s common shares during the three months ended September 26, 2025.

ISSUER PURCHASES OF EQUITY SECURITIES

Period

Total Number of Shares Purchased

Average Price Paid Per Share

Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
(1) (2)

Approximate Dollar Value That May Yet Be Purchased Under the Plans or Programs
(1) (2)

June 28, 2025 - August 1, 2025

—

$

—

—

$

43,342,302

August 2, 2025 - August 29, 2025

102,272

$

114.63

102,272

$

31,618,822

August 30, 2025 - September 26, 2025

30,747

$

105.11

30,747

$

228,386,953

Total

133,019

133,019

(1)
 In February 2020, the Company’s Board of Directors (the “Board”) approved the 2020 Repurchase Plan, authorizing the repurchase of $50.0 million worth of common shares. During the nine months ended September 26, 2025, the Company repurchased 179 thousand shares under the 2020 Repurchase Plan for an aggregate purchase price of $21.1 million and an average price of $118.09 per share. The Company had $28.4 million available for share repurchases under the 2020 Repurchase Plan as of September 26, 2025.
(2) 
In September 2025, the Board approved the 2025 Repurchase Plan, authorizing the repurchase of an additional $200.0 million worth of common shares. No shares have been repurchased under the 2025 Repurchase Plan to date.

I
tem 3. Defaults Upon Senior Securities

None.

I
tem 4. Mine Safety Disclosures

None.

I
tem 5. Other Information

a)
Disclosure in lieu of reporting on a Current Report on Form 8-K
On October 31, 2025, the Board elected Matthew Farrell to the Board to fill the vacancy created by Barbara Hulit’s resignation. Mr. Farrell will serve on the Board and as a member of the Audit Committee of the Board, effective November 2, 2025.
Mr. Farrell will be entitled to the standard compensation paid to non-employee directors as stipulated in the Company’s Non-Employee Director Compensation Policy, including an annual cash retainer for Board service of $67,500, an annual cash retainer for Audit Committee service of $10,000 and an annual equity award with a fair value on the date of grant of $200,000, which will be granted in the form of restricted stock units. Such compensation will be prorated for 2025 to reflect Mr. Farrell’s actual period of service during the year.
In connection with his appointment, Mr. Farrell will enter into the Company’s standard indemnification agreement for directors and officers. Mr. Farrell has no direct or indirect material interest in any related person transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
b)
Material changes to the procedures by which security holders may recommend nominees to the board of directors.
None.

43

c)
Rule 10b5-1 Trading Plans
The adoption or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors during the three months ended September 26, 2025, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (“Rule 10b5-1 Plan”), are summarized below.

Name

Title

Action

Date

Total Shares to Be Sold

Expiration Date

Thomas N. Secor

Director

Adoption

September 11, 2025

1,495

September 11, 
2026

Matthijs Glastra
(1)

Chair of the Board of Directors and Chief Executive Officer

Adoption

September 11, 2025

68,000

July 2, 
2026

(1)
This written plan was adopted through a trust for which Mr. Glastra’s spouse is a trustee.

None of our officers or directors 
adopted 
or 
terminated 
a “non-Rule 10b5-1 trading arrangement” as defined in Item 408 of Regulation S-K
, during the three months ended September 26, 2025.

44

I
tem 6. Exhibits

Incorporated by Reference

Exhibit
Number

Exhibit Description

Form

File No.

Exhibit

Filing
Date

Filed/
Furnished
Herewith

3.1

Certificate and Articles of Continuance of the Registrant, dated March 22, 1999

S-3

333-202597

3.1

03/09/2015

3.2

By-Laws of the Registrant, as amended

10-K

001-35083

3.2

03/01/2021

3.3

Articles of Reorganization of the Registrant, dated July 23, 2010

8-K

000-25705

3.1

07/23/2010

3.4

Articles of Amendment of the Registrant, dated May 26, 2005

10-K

001-35083

3.4

3/1/2023

3.5

Articles of Amendment of the Registrant, dated December 29, 2010

8-K

000-25705

3.1

12/29/2010

3.6

Articles of Amendment of the Registrant, dated May 11, 2016

8-K

001-35083

10.1

05/12/2016

3.7

Articles of Amendment of the Registrant, dated April 29, 2022

10-Q

001-35083

3.6

05/10/2022

10.1

Fourth Amended and Restated Credit Agreement, dated as of June 27, 2025, by and among the Company, Novanta Corporation, Novanta UK Investments Holding Limited, Novanta Europe GmbH, Bank of America, N.A., as Administrative Agent, Swing Line Lender, L/C Issuer and lender, BofA Securities, Inc., as joint lead arranger and joint book runner, JP Morgan Chase Bank, N.A., as joint lead arranger, joint book runner, co-syndication agent and lender, Wells Fargo Securities LLC, as joint lead arranger and joint book runner, Wells Fargo Bank, National Association, as co-syndication agent and lender, PNC Capital Markets LLC, as joint lead arranger and joint book runner, PNC Bank, National Association, as  co-syndication agent and lender, U.S. Bank National Association, as joint lead arranger and co-syndication agent, Silicon Valley Bank, a Division of First Citizens Bank & Trust Company, as documentation agent and lender, Citibank N.A. as lender, and the other parties thereto.

8-K

001-35083

10.1

07/02/2025

31.1

Chief Executive Officer Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

*

31.2

Chief Financial Officer Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

*

32.1

Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

**

32.2

Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

**

101.INS

Inline eXtensible Business Reporting Language (XBRL) Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

*

101.SCH

Inline XBRL Taxonomy Extension Schema Document

*

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*

† Certain schedules or appendices to this exhibit have been omitted pursuant to Regulation S-K Item 601(a)(5). A copy of any omitted schedule will be furnished to the Securities and Exchange Commission or its staff upon request.
* Filed herewith
** Furnished herewith

45

S
IGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Novanta Inc. (Registrant)

Name

Title

Date

/s/ Matthijs Glastra

Chair of the Board of Directors and Chief Executive Officer

November 3, 2025

Matthijs Glastra

/s/ Robert J. Buckley

Chief Financial Officer

November 3, 2025

Robert J. Buckley

46